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1. INTRODUCTION 
Lipids are fats that are either absorbed from food or synthesized by the liver. 
Triglycerides (TGs) and cholesterol contribute most to disease, although all lipids are 
physiologically important1. 
Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis- 
associated conditions, such as coronary heart disease (CHD), Ischemic 
cerebrovascular disease, and peripheral vascular disease. Although the incidence of 
these atherosclerosis-related events has declined in the United States, these conditions 
still account for the majority of morbidity and mortality among middle-aged and older 
adults. The incidence and absolute number of annual events will likely increase over 
the next decade because of the epidemic of obesity and the aging of the U.S 
population. Dyslipidemia, including Hyperlipidemia (hypercholesterolemia) and low 
levels of high-density-lipoprotein cholesterol (HDL-C), are major causes of increased 
atherogenic risk: both genetic disorders and lifestyle (sedentary behaviour and diets 
high in calories, saturated fat and cholesterol) contribute to the dyslipidemia seen in 
developed countries around the world. 
Recognition that dyslipidemia is a risk factor has led to the development of 
drugs that reduce cholesterol levels. There drugs provide benefit in patients across the 
entire spectrum of cholesterol levels, primarily by reducing levels of low-density 
lipoprotein cholesterol    (LDL-C). In well-controlled clinical trials, fatal and non-fatal 
CHD events and strokes were reduced by as much as 30% and 40%2-6. 
Clinical trial data support extending lipid-lowering therapy to high-risk 
patients whose major lipid risk factor is a reduced plasma level of HDL-C, even if 
their LDL-C level does not meet the existing threshold values for initiating 
hypolipidemic drug therapy⁷. In Patients with low HDL-C and average LDL-C levels, 
appropriate drug therapy reduced CHD endpoint events by 20% to 35%⁴’⁸’⁹.  Since 
two-third of patients with CHD in the United States have low HDL-C levels (<40 
mg/dl), it is important to include low-HDL patients in management guidelines for 
dyslipidemia, even if their LDL-C levels are in the normal range¹⁰.  
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2. SUBJECTIVE INTRODUCTION 
Hyperlipidemia is an increase (hyper) in the lipids (lipi), which are a group of 
fats or fat like substances in the blood (demia). Cholesterol and the triglycerides are 
the two lipids in the blood. Elevation of one or both of these lipids is seen in 
hyperlipidaemia. Serum cholesterol levels above 240 mg/dL and triglyceride levels 
above 150 mg/dL are associated with atherosclerosis¹¹. 
Hyperlipidemia is defined in terms of class or classes of elevated lipoproteins 
in the blood, the term Hyperlipoproteinemia is used Hypercholesterolemia refers to 
high triglyceride level in the blood. These statistics illustrate the importance of 
identifying and managing risk factors for CHD. The major  conventional risk factors 
are elevated LDL-C,reduced  HDL-C, cigarette smoking, hypertension, type 2 
diabetes mellitus, advancing age, and a family history of premature(men<55 years; 
Women <65 years) CHD events in a first-degree relative. Control of the modifiable 
risk factors is especially important in preventing premature CHD. 
Observational studies suggest that modifiable risk factors account for 85% of 
excess risk (risk over and above that of individuals with optimal risk-factor profiles) 
for premature CHD¹². The presence of one or more conventional risk factors in 90% 
of patients with CHD belies claims that a large percentage of CHD, perhaps as much 
as 50%, is not attributable to conventional risk factors. 
Severe hypertriglyceridemia (i.e., triglyceride levels of >1000 mg/dl) required 
therapy to prevent pancreatitis. Moderately elevated triglyceride levels (150 to 400 
mg/dl) also are of concern because they often occur as part of the metabolic 
syndrome, which includes insulin resistance, obesity, hypertension, low HDL-C levels 
and substantially increased CHD risk. The atherogenic dyslipidemia in patients with 
the metabolic syndrome is characterized by moderately elevated triglycerides, low 
HDL-C levels, and lipid-depleted LDL (sometimes referred to as “small, dense LDL”) 
¹³′¹⁴.   The metabolic syndrome affects-25% of adults and is common in CHD patients: 
hence, identification of moderate hypertriglyceridemia in a patient, even if the total 
cholesterol level is normal, should trigger an evaluation to identify this disorder¹⁵’¹⁶. 
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CLASSIFICATION OF HYPERLIPIDEMIA 
Hyperlipidemia is classified according to the Frederickson classification which 
based on the pattern of lipoproteins on electrophoresis or ultracentrifugation. It was 
later adopted by the World Health Organization. (WHO) 
Primary Hyperlipidemia 
Upto 60% of the variability in the serum fasting lipids may be genetically 
determined although expression is often influenced by interaction with environmental 
factor.  The familial disorders can be classified as follows. 
Hyperlipoproteinemia Type I 
This is the very rare (also known as Buerger greets syndrome, primary 
Hyperlipoproteinemia of familial hypercholesterolemia) is due to a deficiency of 
lipoprotein lipase (LPL) or altered lipoprotein C2 resulting in elevated chylomicrons, 
the particles that the transfer fatty acids from the digestive tract to the liver. LPL is 
also responsible for the initial breakdown of endogenously made triglycerides in the 
form of VLDL. Defect in LPL also result in elevated VLDL. Its prevalence is 0.1% of 
the Population. 
TABLE.I 
World Health Organization classification of Hyperlipoproteinemia¹⁷ 
Type Plasma Cholesterol 
LDL 
Cholesterol 
Plasma 
triglycerides 
Lipoprotein 
abnormality 
I.  Raised Low or normal Raised Excess chylomicrons 
II a Raised or normal Raised Normal Excess LDL 
II b Raised Raised Raised Excess LDL & VLDL 
III Raised Low or normal Raised Excess  chylomicrons &remnants& IDL 
IV Raised Normal Raised Excess chylomicrons & VLDL 
V Raised Normal Raised Excess chylomicrons & VLDL 
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Hyperlipoproteinemia type II 
Hyperlipoproteinemia type II, by for the most common form, is further 
classified into type II a and type II b, depending mainly on whether there is elevation 
in the triglyceride level in addition to LDL cholesterol. 
Type II a 
This may be sporadic (due to dietary factors) polygenic, or truly familial as a 
result of mutation, either in the LDL receptor gene on chromosome 19 (0.2% of the 
population) or the ApoB gene (0.2%). The familial form is characterized by Tendon 
Xanthoma, Xanthelesma and premature Cardio Vascular diseases. 
Type II b 
The high VLDL levels are due to over production of substrates, including 
triglycerides acetyl Co-A and on increase in B – 100 syntheses. They may also be 
caused by the decreased clearance of LDL. Its prevalence in the population is 10%. 
Hyperlipoproteinemia type III 
This form is due to high triglycerides. It is also known as 
hypertriglyceridemia. According to the NCEP-ATP III detention of high triglycerides 
(>200 mg/dl). Its prevalence is adult 16% of adult population. 
Hyperlipoproteinemia type IV 
This type is very similar to type 1, but with high VLDL in addition to 
chylomicrons. It is also associated with glucose intolerance and Hyperurecemia. 
Unclassified forms 
   Non classified forms are extremely rare 
 Hypo α– lipoproteinemia 
 Hypo β– lipoproteinemia  
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Secondary Hyperlipidemia 
    In the class of secondary hyperlipidaemias there have a number of disorders, 
dietary indiscretion or as a side effect of drug therapy. These account for up to 40% of 
hyperlipidaemias. 
Disease states: 
   Many of the disease states associated with secondary hyperlipidaemias are  
  Non – insulin dependent diabetes 
  Insulin dependent diabetes 
  Hypothyroidism 
  Pregnancy 
  Alcohol abuse 
  Chronic renal failure 
  Cardiac transplantation 
 Myeloma 
Drugs: 
A large number of drugs can affect serum lipid and lipoprotein concentration, 
some of them are 
 Amiodarone 
 Androgens 
  B-Adreno receptor blockers 
  Cyclosporine 
  Diuretics 
  Thiazides 
 Loop diuretics 
 Glucocorticoids 
 Oral Contraceptives 
 Vitamin A derivate 
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 EPIDEMIOLOY⁽³³⁾ 
Total cholesterol and LDL cholesterol increase throughout life in men and 
women representing an atherogenic pattern characteristic of Western society diets 
(Fig.1)¹⁹ Based on the National Health and Nutrition Examination Survey 
(NHANES1999-2000) and the ATP III guidelines, slightly more than 50% or nearly 
105 million American adults over 20 years of age have total cholesterol levels of 200 
mg/dl or higher. ¹⁹′²⁰′²¹ only about one-third are aware that they have 
hypercholesterolemia, and 12% were on therapy for hypercholesterolemia. Changes in 
the NCEP guidelines have increased the number of persons eligible for therapeutic 
lifestyle changes (TLCs) or lipid-lowering therapy by millions. 
NCEP estimates that only 26% of patients have an optimal LDL cholesterol 
(<100 mg/dl) and that large numbers of patients are either untreated or undertreated. 
Unfortunately, the patients at highest risk are less likely to the treated to desirable 
levels of LDL²². Although these numbers appear staggering in their enormity, 
substantial progress has been made, and the number of Americans with a desirable 
blood cholesterol level (<200 g/dL) hasraised to 49% from 45% in the earlier survey 
(1976-1980), whereas the average total cholesterol level in this country has fallen 
from 220 mg/dL in 1960 to 203 mg/dL in 1988-1994. Unfortunately, there has been 
little change in total cholesterol between 1994 and 2000. Patients who are at risk but 
who have not yet experienced their first cardiovascular event (e.g., myocardial 
infraction [MI]) are termed primary prevention, whereas those manifest vascular 
diseases are termed secondary intervention. 
Data from the Framingham Study and from other studies and from other 
studies demonstrate that the risk for developing cardiovascular disease is related to the 
degree of total cholesterol and LDL elevation in a graded, continuous fashion²³. 
Hypercholesterolemia is additive to the other non-lipid risk factors for CHD, 
including cigarette smoking, hypertension, diabetes, low HDL levels, and 
electrocardiographic (ECG) abnormalities. The presence of established CHD prior MI 
increases the risk of MI five to seven times that seen in men or women without CHD, 
and LDL is a significant predictor of subsequent morbidity and mortality²⁴. 
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FIG.1 
 
 
About 50% of all MIs and at least 70% of CHD deaths occur in patients with 
known CHD, and these patients therefore should be a target for screening, 
identification, and treatment. Unfortunately, the identification of patients at high risk 
because of hypercholesterolemia or other lipid disorders is too frequently overlooked 
because blood lipid levels are not always evaluated in this population even after an 
event such as MI²⁵. 
     A comparison of the United States with other countries shows similar 
relationships between total cholesterol and LDL and an inverse relationship with HDL 
and coronary artery disease (CAD) mortality²⁶.  On a positive note, the U.S.mortality 
rate is midway among the countries studied, and this country has had the greatest 
decline in CAD mortality (35% and 40%) in men and women over the last 10 years 
compared with other countries. A decline in the prevalence of hypercholesterolemia in 
certain segments of the U.S. population parallels these trends in mortality. LDL and 
the ration of LDL to HDL also have been used to assess risk, but their use adds little 
information to total cholesterol alone unless HDL is abnormally high or low. HDL 
transports cholesterol from lipid-laden foam cells top the liver. 
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 HDL has been shown to be protective for the occurrence of CHD, and an 
inverse relationship exists between CHD and HDL levels²⁷.  LDL is enriched with 
cholesterol esters and is smaller, denser, and more atherogenic than less-dense VLDL. 
Routine measurement of triglycerides cannot distinguish between the types of VLDL 
present in plasma. Elevation of triglyceride-rich lipoproteins is associated with low 
HDL, and this ration predicts increased risk. The 8-year follow-up of the Copenhagen 
male study found a clear gradient of risk of ischemic heart disease (IHD) with 
increasing triglyceride levels within each level of HDL cholesterol. When compared 
with the lowest tertile of triglyceride concentrations, the highest tertile had 2.2 relative 
risks for IH|D, and the relationship extended across all concentrations of HDL²⁸. 
     The Helsinki Heart Study shows the hypertriglyceridemia and low HDL levels 
are associated with obesity ( body mass index [BMI] >26 kg/m2}, smoking, sedentary 
lifestyle, blood pressure of 140/90mm Hg or greater, and a blood glucose 
concentration above 4.4 mmol/L and that the benefit of gemfibrozil (risk reduction 
68%, p< .03) was confined largely to overweight subjects²⁹. Hypertriglyceridemia in 
certain instances e.g., diabetes mellitus, nephrotic syndrome, and chronic renal 
disease and perhaps in women is associated with increased cardiovascular risk. This is 
thought to be a consequence of the presence of lipoproteins and of 
hypertriglyceridemia being a marker for them, since triglycerides usually are not 
independently predictive for CHD³⁰. 
LIPIDS AND LIPOPROTEINS 
Lipid Terminology 
Some of the complexity for the beginner striving to understand lipid 
metabolism may be due to the terminology used in relation to this topic. For example, 
the terms “cholesterol” and “lipid” may be considered by some to be synonymous, 
and as such, are used without distinction in reference to dyslipidemic conditions. 
Cholesterol is one of the major lipid particles in the body; the other is triglyceride 
(TG). Both of these particles serve important functions; however as insoluble 
molecules, they must be transported in the blood in complexes known as 
lipoproteins³². Plasma lipoproteins are composed of a core of TG and cholesterol 
ester, enveloped by a surface coat of phospholipid, unesterified  
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(“free”) cholesterol, and special proteins called Apo lipoproteins (or Apo proteins). 
The term “lipoprotein” refers to this unique combination of “lipid” and “protein”. 
Several lipoprotein complexes exist, and each is identified according to its density, 
lipid composition, and the Apo lipoproteins on the surface of the particle. 
The five mainclassifications of lipoproteins are chylomicrons, very low-
density lipoprotein cholesterol (VLDL), intermediate-density lipoprotein cholesterol 
(IDL), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein 
cholesterol (HDL). In the laboratory, total cholesterol, TG, and HDL are measured 
directly, from which a calculated estimation of VLDL and LDL cholesterol are 
derived. These measurements of VLDL and LDL are based on a fasting TG level and 
are valid only when the TG level is less than 400 mg/dL (5 mmol/L). This explains 
the requirement for a fasting blood sample (overnight fast of 12 hours) to determine 
blood lipid levels. Direct measurement of VLDL and LDL is also possible; however, 
due to their high cost and technical complexity, these are performedprimarily in 
reference laboratories. 
CLASSIFICATION OF LIPOPROTEINS 
Although cholesterol and TG serve several important functions within the 
body, they are insoluble particles and must be packaged into lipoproteins in order to 
circulate in the plasma, from sites of synthesis or absorption to sites of use. The core 
of the lipoprotein, containing cholesterol ester and TG, is nonpolar and hydrophobic, 
and the outer layer of the lipoprotein particle (contain free cholesterol, phospholipid, 
and specific Apo lipoproteins), is polarized, permitting the lipoprotein particles to be 
transported in the circulation. Apolipoproteins (apo) such as apoB, apoC and apoE, 
coat lipoprotein particulars and serve a number of functions including the transport of 
lipids in the blood and recognition of lipoprotein particles by enzymes which process 
or remove lipids from the lipoprotein particles. For example, apoC-II activates the 
enzyme lipoprotein lipase (LPL), which removes TG from lipoprotein particles such 
as chylomicrons and VLDL. 
Each lipoprotein class (chylomicrons, VLDL, IDL, LDL, and HDL) varies in 
sizes, density and lipid composition within the core of the particle. Within the main 
classes of lipoproteins, there may be further differentiation in to subclasses, but for 
the purposes of this discussion they are referred to as a single lipoprotein. 
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Chylomicrons and VLDL are the largest, most floating particles, having more TG 
within their core; in contrast, LDL and HDL have more cholesterol ester within their 
core and hence, greater particle density. Table II shows the lipoprotein classification, 
including the major lipid component, apolipoprotein associated with each particle, and 
the source of the particle. 
 
TABLE II 
CHARACTERSTICS OF THE MAJOR LIPOPROTEIN CLASSES 
Lipoprotein Density(g/dl) Diameter(nm) Lipid% 
Tg Chol PL 
Chylomicron 0.95 75-1200 80-95 2-7 3-9 
VLDL 0.95-1.006 30-80 55-80 5-15 10-20
IDL 1.006-1.019 25-35 20-50 20-40 15-25 
LDL 1.019-1.063 18-25 40-50 40-50 20-25 
HDL 1.063-1.210 5-12 15-25 15-20 20-30 
 
Chylomicrons 
Chylomicrons are produced in the intestinal lumen following the absorption of 
digested fat. They are the largest lipoprotein and are rich in TG. Because of their 
particle size, chylomicrons scatter more light and may cause the serum to take a 
cloudy appearance after meals or in patients with dyslipidemic syndromes 
characterized by the inability to catabolize chylomicrons and TG rich lipoproteins. 
Chylomicrons are transported in the blood to tissues such as skeletal muscle, fat, and 
the liver. The capillary beds of these tissues contain high concentrations of LPL. LPL 
hydrolyzes TG in the chylomicrons into free-fatty acids that are either oxidized by the 
muscle cells to generate energy, stored in adipose tissue, oxidized in the liver, or used 
in hepatic VLDL synthesis³³. Once the chylomicrons have been processed by LPL, the 
TG-depleted chylomicron is called a remnant particle, which is then transported to the 
liver for further processing. 
VLDL and IDL Cholesterol 
VLDL is a lipoprotein particle similar to chylomicrons, which contains a high 
concentration of TG. VLDL is synthesized from free-fatty acids formed in the 
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catabolism of chylomicrons in the liver, or from endogenous production of TG³⁴. The 
TG component of VLDL also undergoes hydrolysis by capillary LPL to provide fatty 
acids to adipose and muscle tissue. The remaining lipid portion is called IDL. IDL is 
then converted to LDL by enzymatic action of hepatic lipase or is taken up by the 
liver via the LDL receptor. 
LDL Cholesterol 
LDL particles carry the majority of the cholesterol in the blood, supplying 
cholesterol to the cells. LDL receptors in peripheral cells or liver bind with LDL and 
clear it from the blood. Peripheral cells utilize LDL cholesterol for cell membrane 
structure and also the production of hormones. LDL is an atherogenic lipoprotein 
particle, and it is established that higher levels of LDL are associated with increased 
cardiovascular disease risk³⁵. In addition, the heterogeneity of LDL particles 
composition, due to differences in the amount of cholesterol per particle, suggests that 
particle size is an important consideration in the atherogenic potential of the LDL. 
Although the exact mechanism is not fully appreciated, small, dense LDL is thought 
to be more susceptible to oxidative modification and may therefore be more toxic to 
the vascular endothelium. A sequence of immunologic and inflammatory events in the 
arterial wall contributes to atherogenic and the development of atherosclerotic lesions. 
These advanced lesions occlude coronary artery blood flow and contribute to clinical 
presentations such as unstable angina or myocardial infarction³⁶. 
HDL Cholesterol 
It is well established that increased HDL levels are associated with decreased 
risk for coronary heart disease, whereas reduced HDL levels increase risk. The cardio 
protective role of HDL is to facilitate the transfer of cholesterol from atherogenic 
lipoproteins and peripheral tissues to the liver. Although suggestive of a simple 
“reverse transport” process, the exact mechanism, dependent on the interactions 
between HDL apolipoprotein and enzymes activity, is highly complex and poorly 
understood. HDL particles are synthesized and catabolized in the liver and intestines. 
Hopeful HDL obtains free cholesterol from peripheral tissues. A circulating enzyme 
called lecithin: cholesterol acyltransferase promotes the uptake of free cholesterol by 
HDL by a reaction called esterification. The esterification of free cholesterol into 
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cholesterol ester produces a more hydrophobic core, enhancing the density of the 
HDL particle. Another enzyme, cholesteryl ester transfer protein, mediates the 
transfer of cholesterol ester of the HDL, core and other circulating lipoproteins such 
as LDL³⁷. 
Lipoprotein (a) 
Lipoprotein (a) [LP (a)] is another lipoprotein particle which in structure is 
very similar to LDL with the addition of apolipoprotein (a). LP (a) links lipid 
metabolism with blood coagulation, ³⁸and because of the structural similarities of the 
LP (a) particle to both LDL and plasminogen, it is thought that this particle has both 
atherogenic and thrombogenic potential³⁹. LP (a) may inhibit thrombolysis and 
elevated levels are linked to increased risk for coronary heart disease⁴⁰; this risk 
appears greater in the presence of elevated LDL cholesterol levels.⁴¹ 
Apolipoproteins 
Several apolipoprotein have been identified; Table II shows the 
Apolipoprotein associated with each class of lipoprotein. Apolipoprotein have many 
roles in lipid metabolism, which represented in Table III. 
Table III 
APOLIPROTEINS IN METABOLISM 
APOLIPOPROTEIN (APO) FUNCTION 
ApoE (E2, E3, E4) Responsible for mediating the uptake of remnants 
particles, either chylomicron remnants, VLDL, or 
IDL remnants 
ApoB-100 Present in VLDL and LDL, acts as ligand for the 
LDL Receptor 
ApoB-48 Found in chylomicrons and intestinal cells 
ApoC (C-I,C-II,C-III) Found on chylomicrons, VLDL and HDL particles. 
ApoB-II activates LPL catabolize  
TG. ApoC-III may inhibit action of LPL 
Apo-A-I Present in chylomicrons and HDL particles. 
Activated lecithin; cholesterol acyltransferase 
enzyme and provides structure to HDL particles 
Apo-A-II Present in chylomicrons and HDL particles. 
Activated hepatic triglyceride lipase. 
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Lipid Processing Enzymes 
Table III lists several major enzymes involved in lipoprotein metabolism that 
have been identified. Activated by the apolipoprotein, these enzymes serve a unique 
role, but not all are completely understood. Table IV 
TABLE IV 
ENZYMES IN LIPOPROTEIN METABOLISM 
ENZYME FUNCTION 
Lipoprotein lipase Hydrolyzes TG in chylomicrons and 
VLDL 
Lecithin-cholesterol acyltransferase Esterifies free cholesterol on the HDL 
surface 
Hepatic-triglyceride lipase Hydrolyzes TG in IDL and HDL particles
Cholesterol ester transfer protein Facilitates transfer between lipoprotein 
cholesterol esters and TG 
 
LIPID GENERATION AND TRANSPORT 
There are three main pathways responsible for the generation and transport of 
lipids within the body. These pathways include the exogenous pathway, the 
endogenous pathway, and the pathway of reverse cholesterol transport.¹⁹′⁴² 
Exogenous (Dietary) Lipid Pathway 
Following digestion and absorption of dietary fat, TG and cholesterol are 
packaged to form chylomicrons interact at the capillaries of adipose tissue and muscle 
cells releasing TG to the adipose tissue to be stored and available for the body’s 
energy needs. The enzyme LPL hydrolyzes the TG and free-fatty acids are released.  
Some of the components of the chylomicrons are “repackaged” into other 
lipoproteins, for example, some apolipoprotein are transferred to HDL, and the 
remaining chylomicrons remnant particles are removed from the plasma from the 
plasma by way of chylomicron remnant receptors present on the liver. 
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Endogenous Pathway 
The endogenous pathway involves the liver synthesizing lipoproteins. TG and 
cholesterol ester are generated by the liver and packaged into VLDL particles and 
then released into the circulation. VLDL is then processed by LPL in tissues to release 
fatty acids and glycerol. The fatty acids are taken upon by muscle cells for energy or 
by the adipose cells for storage. Once processed by LPL, the VLDL becomes a VLDL 
remnant. The majority of the VLDL remnants are taken up by the liver via the LDL 
receptor, and the remaining remnant particles become IDL, a smaller, denser 
lipoprotein than VLDL. The fate of some of the IDL particles requires them to be 
reabsorbed by the liver (again by the LDL receptor); however other IDL particles are 
hydrolysed in the liver by hepatic-triglyceride lipase to form LDL, smaller, denser 
particle than IDL. 
LDL is the main carrier of circulating cholesterol within the body, used by 
extra-hepatic cells for cell membranes and steroid hormone synthesis. Much of the 
LDL, particles are taken up by LDL, receptors in the lever, the remaining LDL, is 
removed by way of scavengers pathway at the cellular level. As LDL is taken up by 
receptors free cholesterol is releasedand accumulates within the cells. LDL receptor 
activity ad uptake of LDL regulate plasma LDL concentration by several mechanisms, 
including decreasi9ng the synthesis of hyddroxy-3-methyl glutaryl coenzyme A 
(HMG-CoA) reductive (which controls rate of cholesterol synthesis), suppressing the 
synthesis of new LDL receptors in the cells and activating the enzyme, acyl-
coenzyme A cholesterol acyltransferase, which esterified free cholesterol into 
cholesterol ester, storing cholesterol in the cell⁴³. 
Reverse Cholesterol Transport 
Reverse Cholesterol transport refers to the process by which cholesterol is 
removed from the tissues and returned to the liver⁴⁴. HDL is the key lipoprotein 
involved in reverse cholesterol transport and the transfer of cholesteryl esters between 
lipoprotein⁴⁵. The smallest and most dense lipoprotein particle is HDL. HDL is 
formed through a maturation process whereby precursor particles (nascent HDL) 
secreted by the liver and intestine proceed through a series of conversions (known as 
the “HDL cycle”) to attract cholesterol from cell membranes and free cholesterol to 
Subjective Introduction 
Department of Pharmacy Practice, K.M.College of Pharmacy                                   Page | 15  
 
the core of the HDL particle. There are subclasses of HDL particles, including HDL₂ 
and HDL₃. The exact mechanism by which the HDL delivers cholesterol esters to the 
liver is not well understood, but several mechanisms have been suggested. These 
include the Action of cholesteryl ester transfer protein, which transforms HDL 
into TG-rich particle that interacts with hepatic-triglyceride lipase. Cholesterol ester-
rich HDL may also be taken up directly by the receptors in the liver. Another 
mechanism may be that cholesterol esters are delivered directly to the liver for uptake 
without catabolism of the HDL cholesterol particle⁴⁴′⁴⁶. 
In the context of cardiovascular disease risk, it is established that higher levels 
of HDL are associated with lower levels of heart disease; therefore higher levels of 
HDL are considered to be protective⁴⁷. In contrast, it is now appreciated that other 
lipoproteins, including VLDL, IDL, LDL, andthe remnant particles rendered in lipid 
processing, are highly atherogenic. To reflect this, the term “non-HDL cholesterol” 
has been invoked to describe this increased risk reflected in the lipid profile that may 
not be otherwise identified by simply examining the LDL alone⁴⁸. Non-HDL 
cholesterol therefore encompasses a broader indication of cardiovascular disease risk. 
This parameter is calculated by equation {non-HDL cholesterol=total cholesterol-
HDL} and is an important consideration in ensuring that patients are treated 
appropriately to target levels. 
 LIPOPROTEIN DISORDERS⁴⁹ 
There are five primary inherited lipoprotein disorders which disturb lipid 
metabolism at the points these are: 
  Familial hypertriglyceridemia (FHTG) (unknown), including lipoprotein 
lipase (LPL) deficiency, in which low LPL activity results in decreased removal, and 
thus increase of serum triglyceride; there is increased hepatic secretion and thus 
raised plasma concentration of triglyceride-rich VLDL. Patients are at risk of 
recurrent acute pancreatitis when plasma triglycerides exceed 10 mmol/l, and 
especially 20 mmol/l. 
  Familial combined hyperlipidaemia (FCHL) (common and most important) 
in which there is increased hepatic secretion if apolipoprotein B containing VLDL, 
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and conversion to LDL; in consequence plasma LDL and VLDL are raised. Patients 
exhibit macro vascular disease (coronary heart, peripheral and cerebral) 
Remnant removal disease (RRD), also called remnant lipaemia, familial 
dysbetalipoproteinemia) (uncommon) in which there is a defect of apolipoprotein E. 
This is the major ligand that allows internalized and subsequent metabolism of 
remnant particles derived from VLDL and chylomicrons. The consequence is 
accumulation of VLDL remnant called intermediate density lipoprotein (IDL) with 
cholesterol and triglycerides usually in the range 6-9 mmo1/1. Patients experience 
severe macro vascular disease. 
Familial hypoalphalipoproteinemia (rare) in which the serum concentration 
of (protective) HDL is low. Coronary heart and peripheralvascular disease result. 
Familial hypercholesterolemia (FH) (common) is characterized by 
elevations of total and LDL cholesterol to plasma. In the more severe heterozygous 
form this affects about 1:500 of the population (one copy of the LDL-receptor protein 
is absent or defective). LDL-cholesterol is elevated from childhood. Untreated, half 
the males will be dead by 60 years, females 10 years later. The principal consequence 
is coronary heart, but occasionally also peripheral and cerebrovascular disease. 
CONSEQUENCES OF LIPID ABNORMALITIES 
  Dyslipidemia is a major risk factor for atherosclerosis is a disease process that 
affects the coronary, cerebral and peripheral arterial circulation. 
Coronary Heart Disease (CHD)⁵⁰ 
The etiology of atherosclerosis is multi factorial but the cause-effect 
relationship between dyslipidaemia and atherosclerosis has been shown in many 
studies and trials. 
The reducing the plasma LDL cholesterol level sharply reduces the risk of 
subsequent clinical CHD in both patients with pre-existing CHD and in patients free 
of CHD. There is no doubt about the atherogenesisi of LDL. Evidence suggests that 
oxidative modification of LDL within the artery is necessary for mediating its 
atherogenicity. 
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An atherogenic lipoprotein pattern. Characterised by a predominance of small 
dense LDL, moderately elevated plasma triglycerides and low levels is the most 
powerful risk factor for CAD. 
Stroke⁵¹ 
Stroke is a term that describes a clinical event caused either by occasion or 
haemorrhage in the arterial supply to the central nervous system resulting in tissue 
infraction. It is one of the most distributing consequences of vascular disease. 
Atheroma formation is the root of pathogenesis of thromboembolic stroke. 
Observational studies suggested that dyslipidaemia particularly high LDL-C, low 
HDL-C and high TG are important risk factors for thrombi-embolic stroke. 
Peripheral Artery Disease (PAD) ⁵² 
Peripheral artery disease is most commonly a manifestation of systemic 
atherosclerosis in which the arterial lumen of the lower extremities becomes 
progressively occluded by atherosclerotic plaque. High lipoprotein concentrations are 
important in the development of PAD 
Evidence that atherosclerosis in the peripheral circulation should be 
considered in the same manner as atherosclerosis in the coronary circulation. Patients 
with PAD, even in the absence of a history of myocardial infraction or stroke, have 
approximately the same relative risk of death from cardiovascular causes as do 
patients with a history of coronary of cerebrovascular disease. 
PATIENT RELATED RISK FACTORS⁵³ 
Diabetes Mellitus 
    Premature atherosclerotic disease is the main cause of reduced life expectancy 
in patients with diabetes. 
    Type 1 Diabetes in patients with type 1 diabetes HDL-C may appear high 
    Type 2 Diabetes patients with type 2 diabetes typically have increased 
triglycerides and decreased HDL-C 
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Hypothyroidism 
Abnormality of serum lipid and lipoprotein levels is common in patients with 
untreated hypothyroidism. It is an important cause of secondary dyslipidaemia. 
Chronic renal failure⁵⁴ 
Dyslipidemia is frequently seen in patients with renal failure in the predialysis 
phase, during haemodialysis or when undergoing chronic ambulatory peritoneal 
dialysis. 
Nephrotic syndrome 
Dyslipidemia appears to be caused by an increased production of apolipoprotein 
B-100 and associated LDL-C. 
Obesity 
Chronic, excessive intake of calories leads to increased concentrations of 
triglycerides and reduced HDL-C 
Alcohol 
In the heavy drinker the high caloric content of beer and wine may be a cause of 
obesity with its associated adverse effects on the lipid profile. In addition, alcohol 
increases hepatic triglycerides synthesis, which in turn produces 
hypertreiglyceridemia. 
Drugs⁵⁵ 
A number of drugs can adversely affect serum lipid and lipoprotein 
concentration. 
Antihypertensive agents 
Hypertension is a major risk factor for atherosclerosis, and the beneficial 
effects of lowering blood pressure are well recognized. 
 
 
Subjective Introduction 
Department of Pharmacy Practice, K.M.College of Pharmacy                                   Page | 19  
 
 Diuretics 
Thiamine and loop diuretics increase VLDL-C and LDL-C by mechanisms that 
are not completely understood 
β- blockers 
The effect of β- blockers on lipoprotein metabolism is reflected in an increase 
in serum triglycerides concentrations, a decrease in HDL-C, there is no visible effect 
on LDL- 
Oral Contraceptives    
Estrogens cause a slight increase in hepatic production of VLDL-C and HDL-
C reduce serum LDL-C levels. In contrast progestogens increase LDL-C and reduce 
serum HDL-C and VLDL-C. 
Corticosteroids 
Administrations of glucocorticoids, for example prednisolone, have been 
shown to increase TC and triglycerides by elevating LDL-C and, less consistently, 
VLDL-C. 
Ciclosporin 
Ciclosporin is primarily used to prevent tissue rejection in recipients of renal, 
hepatic and cardiac transplants. Its use has been associated with increased LDL-C 
levels. Hepatic microsomal enzyme inducers. 
 
Drugs such as carbamazepine, phenytoin, phenobarbital, rifampicin and 
griseofulvin, which increase hepatic microsomal enzyme activity, can also increase 
serum HDL-C. The administration of these drugs may also give rise to a slight 
increase in LDL-C and  VLDL-C. 
 
 PATHOLOGY OF DYSLIPIDEMIA 
Dyslipidemia “refers to an abnormality within the lipid profile, encompassing a 
variety of disorders relating to elevations in total cholesterol, LDL, or TG, or 
conversely, lower levels of HDL. The dyslipidemia may present as a single disorder 
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affecting only one lipoprotein parameter, or may represent a combination of 
lipoprotein abnormalities, such as elevated TG and low HDL. 
 
A dyslipidemia may be the result of over-production or lack of clearance of the 
lipoprotein particles, or related to other defects in the apolipoprotein or enzyme 
deficiencies. The pathway and means of lipid metabolism in the human body reflect 
complex processes, and genetics, certain medical conditions, medications, and/or 
environmental factors may influence lipoprotein metabolism in some capacity, 
resulting in a dyslipidemic condition. In the clinical setting, a primary dyslipidemia 
typically refers to a genetic defect in the lipid metabolism as a cause of the problem³⁶. 
 
A secondary dyslipidemia may be attributed to another cause. For example, 
environmental factors (such as a diet rich in saturated fat or a sedentary lifestyle), 
diseases (such as diabetes, hypothyroidism, obstructive liver disease), and 
medications (such as thiazide diuretics, progestins, or anabolic steroids) may result in 
a secondary dyslipidemia⁵⁷ˈ⁵⁸. 
CLINICAL PRESENTATION 
General 
 Most patients are asymptomatic for many years prior to clinically evident 
disease. 
 Patients with the metabolic syndrome may have three or more of the 
following: abdominal obesity, atherogenic dyslipidemia, raised blood 
pressure, insulin resistance with or without glucose intolerance, 
prothrombotic state, or protinflammatory state. 
Symptoms 
 None to chest pain, palpitations, sweating, anxiety, shortness of breath, 
loss of consciousness or difficulty with speech or movement, abdominal 
pain, and sudden death. 
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 Signs 
  None to abdominal pain, pancreatitis, eruptive Xanthomas, peripheral 
polyneuropathy, high blood pressure, body mass index greater than 30 kg/m2, 
or waist size greater than 40 inches in men (35 inches in women). 
Laboratory tests 
 Elevations in total cholesterol, LDL, triglycerides, apolipoprotein B, and C- 
reactive protein. 
 Low HDL. 
Other diagnostic test 
  Lipoprotein (a), homocysteine, serum amyloid A, and small, dense LDL 
(pattern B). 
 Various screening test for manifestations of vascular disease (ankle-brachial 
index, exercise testing, and magnetic resonance imaging) and diabetes (fasting 
glucose, oral glucose tolerance test). 
 MANAGEMENT OF DYSLIPIDEMIA 
The current NCEP guidelines for management of patients are of two types. 
One is a population-based approach to reduce CHD risk, which includes 
recommendations to increase exercises (to expend-2000 calories/week) and to lower  
blood cholesterol by dietary recommendations: reduce total calories from fat to less 
than 30% and from saturated and trans fats to less than 10%; consume less than 
300mg of cholesterol per day; eat a variety of oily fish twice a week⁵⁹ and oils/foods 
rich in linoleic acid (canola, flaxseed and soybean oils, flaxseed and walnuts); and 
maintain desirable body weight. The second is the patient0based approach that 
focuses on lowering LDL-C levels as the primary goal of therapy⁶⁰ 
The guidelines for the management of adults 20 years and older recommended 
a complete fasting lipoprotein profile (total cholesterol, LDL-C, HDL-C, and 
triglycerides). The classification of lipid levels is shown in (Table V). 
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TABLE-V 
CLASSIFICATION OF PLASMA LIPID LEVELS 
Test Normal Values 
Serum Cholesterol American Heart 
Association 
recommendation 
Normal up to 200 mgs/dl 
Borderline Up to 239 mgs/dl 
Elevated if>240 mgs/dl. On repeated values 
Serum Triglycerides <180 mgs/dl. Normal.  Values vary depending on diet, 
alcohol, metabolic state, exercise etc. Elevation of 
values to be considered only if repeated values are high. 
HDL Cholesterol 30-60 mgs/dl 
LDL Cholesterol 100-190 mgs/dl Borderline 
>190 mgs/dl Risk 
Formula for calculating LDL Cholesterol is INVALID if 
TGL>400 mgs/dl 
Total/HDL ratio <4 Normal 
4-6 Low Risk 
>6 High Risk 
 
If the values or total cholesterol, LDL-C, and triglycerides are in the lowest 
category and the HDL-C level is not low, lifestyle recommendations (diet and 
exercise) should be made to ensure maintenance of a normal lipid profile. Other 
vascular disease risk factors (Table VIII), if present should be assessed and treated 
individually. For patient with elevated levels of total cholesterol, LDL-C, or 
triglycerides, or reduced HDL-C values, further treatment is based on the patient’s 
risk-factor status (Table VIII), and calculation of the Framingham risk score (Table of 
primary prevention patients with two or more risk factors. 
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TABLE VI 
Risk Factors for Coronary Heart Disease 
Age Male >45 years or female > 55 years 
Family history of premature CHD A first-degree relative (male below 55 
years or female below 65 years when the 
first CHD clinical event occurs 
Current cigarettes smoking Defined as smoking within the preceding 
30 days 
Hypertension Blood pressure = 140/90 or use of 
antihypertensive medication, irrespective 
of blood pressure 
Low HDL-C <40 mg/dl (consider <50mg/dl as “low” 
for women) 
Obesity Body mass index > 25 kg/m² and waist 
circumference above  40 inches (men) or 
35 inches (Women) 
 
All patients who meet the criteria for lipid-lowering therapy should receive 
instruction about therapeutic lifestyle change. Dietary restrictions include less than 
7% of calories from saturated and trans fatty acids, less than 200 mg of cholesterol 
daily, up to 20% of calories from monounsaturated fatty acids, up to 10% of calories 
from polyunsaturated fat, and total fat calories ranging between 25% and 35% of all 
calories. Two oily fish meals per week are especially important for post-myocardial 
infraction patients due to a substantial reduction in the risk of sudden cardiac death. 
Patients with CHD or a CHD equivalent (symptomatic peripheral or carotid vascular 
disease, abdominal aortic aneurysm, 20% 10-year CHD risk, or diabetes mellitus) 
should immediately start appropriate lipid-lowering drug therapy irrespective of their 
baseline LDL-C level⁶¹. Patients without CHD or CHD equivalent should be managed 
with lifestyle advice (diet, exercise, weight management) for 3 to 6 months before 
drug therapy is implemented. 
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Risk Assessment Using Framingham Risk Scores⁶² 
The 2001 NCEP guidelines and those of the European Atherosclerosis Society 
employ risk assessment tables devised from the Framingham Heart study in an 
attempt to match the intensity of treatment to the severity of CHD risk in patients 
without a prior history of symptomatic atherosclerotic vascular disease. High risk or 
“CHD equivalent” status is defined as >20% chance of sustaining a CHD event in the 
next 10 years. The tables used to determine a patient’s absolute risk do not take in to 
account risk associated with a family history of premature CHD or obesity. As a 
consequence, the risk may be seriously underestimated, resulting in insufficiently 
aggressive management⁶³. After calculation of the risk score, more aggressive therapy 
should be considered for obese patient with family history of premature CHD. It is 
also unlikely that the Framinghamrisks model is appropriate for assessing risk in all 
ethnic groups. 
Arterial Wall Biology Plaque Stability 
More effective lipid-lowering agents and a better understanding of 
atherogenesisi have helped to prove that aggressive lipid-lowering therapy has many 
beneficial effects over and above those obtained by simply decreasing lipid deposition 
in the arterial wall.  Arterigraohic trails have shown that, although aggressive lipid 
lowering results only in very small increases in lumen diameter, it promptly decreases 
acute coronary events. Lesions causing less than 60% occlusion are responsible for 
more than two-thirds of the acute events through its positive effects on the arterial 
wall; it corrects endothelial dysfunction, corrects abnormal vascular reactivity(spasm), 
and increases plaque stability⁶⁴. 
Atherosclerotic lesions containing a large lipid core, large numbers of 
macrophages, and a poorly formed fibrous cap are prone to plaque rupture and acute 
thrombosis. Aggressive lipid lowering appears to alter plaque architecture. Resulting 
in fewer lipids, less macrophages, and a larger collagen and smooth muscle cell-rich 
fibrous cap. Stabilization of plaque susceptibility to thrombosis appears to be a direct 
result of LDL-C lowering or an indirect result of changes in cholesterol and 
lipoprotein metabolism or arterial wall biology⁶⁵′⁶⁶. 
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Gender 
Both men and Women benefit from lipid-lowering therapy. Stains, rather than 
hormone-replacement therapy, are now the recommended first-line drug therapy for 
lowering lipids in postmenopausal women. This recommendation reflects the 
increased CHD morbidity in older women with established CHD who were treated 
with hormone-replacement therapy⁶⁷. 
Age 
Age >45 years in men and >55 years in women is considered to be a CHD risk 
factor. The stain trials have shown that patients >65 of age benefit from therapy as 
much as do younger patients⁶⁸. 
Cerebrovascular Disease Patients: 
In most observational studies, plasma cholesterol levels correlate positively 
with the risk of ischemic stroke. In clinical trials, statins reduced stroke and transient 
ischemic attacks in patients with and without CHD⁶⁹. 
Peripheral Vascular Disease Patients: 
Stains are beneficial in patients with peripheral vascular disease⁶⁹. 
Hypertensive Patients and smokers: 
The risk reduction for coronary events in hypertensive patients and in smokers 
is similar to that in subject without these risk factors⁷⁰. 
Type 2 Diabetes Mellitus: 
Patients with type 2 diabetes benefit very significantly from aggressive lipid 
lowering⁶⁹. 
Post-Myocardial Infraction or Revascularization Patients: 
A soon as CHD is diagnosed, it is essential to begin lipid-lowering therapy 
(NCEP guidelines: LDL-C goal <70 mg/dl for very high-risk patients. Compliance 
with drug therapy is greatly enhanced if treatment is initiated in the hospital⁷¹. It 
remains to be determined if stain therapy alters restenosis after angioplasty; however, 
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the NHLBI Post Coronary Artery Bypass Graft trail showed that statin therapy 
improved the long-term outcome after bypass surgery and that the lower the LDL-C, 
the better⁷². 
Low Cholesterol levels 
Observational studies initially were confusing. In the United States and 
western Europe, low cholesterol levels were associated with an increase in noncardiac 
mortality from chronic pulmonary disease, chronic liver disease, cancer (many 
primary sites), and haemorrhagic stroke. However, more recent data indicate that it is 
the noncardiac diseases that cause the low plasma cholesterol levels and not the low 
cholesterol levels that cause the noncardiac diseases. Once exception may be 
haemorrhagic stroke. In the Multiple Risk Factor Intervention Trial (MRFIT), 
haemorrhagic stroke occurred more frequently in hypertensive patients with total 
cholesterol levels below 1460 mg/dl; however, the increased incidence of 
haemorrhagicstroke was more than offset by reduced CHD risk due to the low 
cholesterol were not associated with increases in haemorrhagic stroke or any other 
cause of noncardiac mortality⁷⁴. 
A betalipoproteinemia and hypo betalipoproteinemia, two rare disorders 
associated with extremely low total cholesterol levels, are instructive because affected 
individuals have reduced CHD risk and no increase in noncardiac mortality. Patients 
who are homozygous for the mutations that cause these disorders have total 
cholesterol levels below 50 mg/dl and triglyceride levels below 25 mg/dl⁷⁵. 
Individuals consuming very low levels of total fat (less than 5% of total 
calories) and vegetarians, who consume no animal fat, usually have total cholesterol 
levels below 150 mg/dl have no increase in noncardiac mortality. 
Based on the lack of harm associated with low total cholesterol levels in these 
various groups, reducing cholesterol levels to similarly tow levels with drugs does not 
appear to be contraindicated. With the advent of more efficacious cholesterol-
lowering agents, it soon may be possible to test the benefits and risks of lowering total 
cholesterol levels below 150 mg/dl. Whether even lower cholesterol levels will 
translate in to a further reduction in clinical events is not known, but many researchers 
are optimistic⁷⁶. 
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 Diabetic dyslipidemia 
Diabetes mellitus is an independent predictor of high risk for CHD. CHD 
morbidity is two to four times higher in patients with diabetes than in nondiabetics, 
and themortality from CHD is up to 100% higher in diabetic patients over a 6-year 
period. Glucose control is essential but provides only minimal benefit with respect to 
CHD prevention. Aggressive treatment of diabetic’s dyslipidemia through diet, 
weight control, and drugs is critical in reducing risk⁷⁷. 
Diabetic dyslipidemia is usually characterized by high triglycerides, low HDL-
C, and moderate elevations of total cholesterol and LDL-C. In fact, diabetes without 
diagnosed CHD has the same level of risk as nondiabetics with established CHD⁷⁸. 
Thus, the dyslipidemia treatment guidelines for diabetic patients are the same as for 
patients with CHD, irrespective of whether the diabetic patient has had a CHD event. 
The first line of treatment for diabetic dyslipidemia usually should be a statin⁷⁹. 
Metabolic Syndrome 
There is an increased CHD risk associated with their insulin-resistant, 
prediabetic state described under the rubric of “metabolic syndrome”. The prevalence 
of metabolic syndrome among patients with premature vascular disease may be as 
high as 50% 
Treatment should focus on weight loss and increased physical activity. Since 
being overweight or obese usually precludes optimal risk factor reduction. Specific 
treatment of increased LDL-C and triglyceride levels HDL-C levels should also be 
undertaken⁸⁰. 
Hypertrigly ceridemia 
There is increased CHD risk associated with the presence of triglyceride levels 
above 150 mg/dl. The treatment is recommended based on the degree of elevation. 
Weight loss, increased exercise, and alcohol restriction are important for all 
hypertriglyceridemic patients. If triglycerides remain above 200 mg/dl after the LDL-
C goal is reached, further reduction in triglycerides may be achieved but increasing 
the dose of a statin or of niacin. Combination therapy (statin plus niacin or statin plus 
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fibrate) may be required, but caution is necessary with these combinations to avoid 
myopathy⁸¹. . 
Low HDL cholesterol. 
Low HDL is a strong independent risk predictor of CHD. The ATP III 
redefined low HDL cholesterol as less than 40 mg/dL but specified no goal for HDL 
cholesterol raising⁸². Low HDL may be a consequence of insulin resistance, physical 
inactivity, type 2 diabetes, cigarettes smoking, very high carbohydrate intake, and 
certain drugs⁸³. In low HDL, the primary target remains LDL according to the ATP 
III, but emphasis shifts to weight reduction, increased physical activity, and smoking 
cessation and, if drug therapy is required, to fabric acid derivatives and niacin. Niacin 
has the potential for the greatest increase in HDL, and the effect is more pronounced 
with regular or immediate0release forms than with sustained-release forms⁸⁴ 
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TABLE VII 
HYPOLIPIDEMIC DRUGS 
 
Drugs Lipoprotein 
class affected 
Common side 
effects 
Contraindications 
HMG-CoA reductase    inhibitors  
Lovastatin 20-80 mg/d 
Pravastatin 40-80 mg qhs 
Simvastatin 20-80 mg qhs 
Fluvastatin 20-80 mg qhs 
Atorvastatin 10-80 mg qhs 
Resuvastatin 10-40 mg qhs 
↑LDL 25-55% 
↑TG 10-20% 
↑HDL 5-10% 
Myalgias, 
Arthralgias, 
Transaminases, 
dyspepsia 
Acute or chornic 
liver disease of 
myositis increased by 
impaired renal 
function and in 
combination with a 
fibrate 
Nicotinic acid ↑LDL 15-25% 
↑TG 25-35% 
↑HDL  15-
30% 
Flushing(may be 
relieved by 
aspirin ), hepatic 
dysfunction, 
nausea, diarrhea, 
glucose 
intolerance, 
hyperuricemia 
Peptic ulcer disease, 
hepatic disease, gout 
Fish oils 3-12g qd ↑TG 5-10% Dyspepsia, 
diarrhea, fishy 
odor to breath 
 
Cholesterol absorption inhibitors 
Ezetimibe 10 mg qd 
↑LDL 18% 
↑TG 8% 
Transaminases  
Bile acideswquestrant 
Cholestyramine 4-32 g qd 
Cholestipol 5-40 g qd 
Colesevelam 3750-4375 mg qd 
Fibric acid derivaties 
Gemfibrozil 600 mg bid 
Fenofibrate 160 mg qd 
Immediate release 100mg tid. 
Gradual increase to 2gtid 
Sustained release 250 mg- 1.5 g bid 
Extended released 500 mg-2 g qhs 
↑LDL 20-30% 
↑TG 10% 
↑HDL 5% 
↑or↓ LDL 
↓TG 25-40% 
↓HDL 5-15% 
Constipation, 
gastric 
discomfort, 
nausea 
Absorption of 
other drugs  
Gallstones, 
dyspepsia, 
hepatic 
dysfunction, 
Myalgia 
Biliary tract 
obstruction, gastric 
outlet obstruction 
Hepatic or biliary 
disease, renal 
insufficiency 
associated with↑ risk 
of myositis 
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Statins 
The statins are the most effective and best-tolerated agents for treating 
dyslipidaemia. These drugs are competitive inhibitors of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, which catalyses an early, rate-limiting step in 
cholesterol biosynthesis,. Higher doses of the more potent statin (e.g., atorvastatin and 
simvastatin) also can reduce triglyceride levels caused by elevated VLDL levels. 
Some statins also are indicated for raising HDL-C levels, although the clinical 
significance of these effects on HDL-C remains to be proven⁸⁵. 
History 
Statins were isolated from a shape, Penicillin citrinum, and identified as 
inhibitors of cholesterol biosynthesis in 1976 by Endo and colleagues. Subsequent 
studies by Brown and Goldstein established that statins act by inhibiting HMG-CoA 
reductase. The first statin studied in humans was compacting, renamed mevastatin, 
which demonstrated the theraptic potential of this class of drugs. However, albert and 
colleagues at Merck developed the first statin approved for use in humans, lovastatin 
(formerly known as mevinolin), which was isolated from Aspergillums terreus. Five 
other statins are also available. Pravastatin and simvastatin are chemically modified 
derivatives of lovastatin. Atorvastatin, fluvastatin, and rosuvastatin are structurally 
distinct synthetic compounds⁸⁶. 
Mechanism of Action 
    Statins exert their major effect reduction of LDL levels through a mevolonic 
acid-like moiety that competitively inhibits HMG-CoA reductase. By reducing the 
conversion of HMG-CoA to mevalonate, statins inhibit an early and rate-limiting step 
in cholesterol biosynthesis⁸⁷. 
Bile-Acid sequestrants 
The two established bile-acid sequestrants orresins (cholestyramine and 
colestipol) are among the oldest of the hypolipidemic drugs, and they are probably the 
safest, since they are not absorbed from the intestine. These resins are also 
recommended for patients 11 to 20 years of age. Because statins are so effective as 
monotherapy, the resins are most often used as second agents if statin, therapy does 
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not lower LDL-C levels sufficiently. When used with a statin, cholestyramine and 
colestipol usually are prescribed at submaximal doses. Maximal doses can reduce 
LDL-C by up to 25% but are associated with unacceptable gastrointestinal side effects 
(bloating and constipation) that limit compliance⁸⁸. 
Niacin (Nicotinic Acid) 
The hypolipidemic effects of niacin require larger doses than are required for 
its vitamin effects. Niacin is the best agent available for increasing HDL-C 
(increments of 30% to 40%); it also lowers triglycerides by 35% to 45 % (as 
effectively as fibrates and the more potent statins) and reduces LDL-C levels by 20% 
to 30%.⁸⁹ 
Fibric Acid Derivatives: PPAR Activators 
Total mortality was significantly greater in the clofibrate group. The increased 
mortality was due to multiple causes, including cholelithiasis. Interpretation of these 
negative results was clouded by failure to analyse the data according to the intention-
to-treat principle. A later analysis demonstrated that the apparent increase in 
noncardiac mortality did not persist in the clofibrate-treated patients after 
discontinuation of the drug⁹⁰. 
Ezetimibe and the Inhibition of Dietary Cholesterol uptake 
Ezetimibe is the first compound approved for lowering total and LDL-C levels 
that inhibits cholesterol absorption by enterocytes in the small intestine. It lowers 
LDL-C levels by about 18% and is used primarily as adjunctive therapy with statins. 
Outcome studies employing Ezetimibe with statins are beginning, but no result are 
anticipated for several years⁹¹. 
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3. DRUG PROFILE 
Atorvastatin calcium  
DESCRIPTION 
Atorvastatin is a synthetic lipid-lowering agent.  Atorvastatin is an inhibitor of 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.  This enzyme 
catalyses the conversion of HMG-CoA to mevalonate, an early and rate-limiting step 
in cholesterol biosynthesis. 
Atorvastatin calcium is very slightly soluble in distilled water, pH 7.4 
phosphate buffer, and acetonitrile; slightly soluble in ethanol; and freely soluble in 
methanol. 
CHEMICAL NAME 
Atorvastatin calcium is [R-(R*, R*)]-2-(4-flurophenyl), β, d-dihydroxy-5-(1-
methylethyl) -3- phenyl- 4- [(phenyl amino) carbonyl]-1Hpyrrole-1- heptanoicacid, 
Calcium salt (2:1) trihydrate. 
Molecular Weight is 1209.42. 
Structural formula is: 
 
 
EmpiricalFormula (C₃₃H₃₄FN₂O₅)2Ca.3H₂O) 
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CLINICAL PHARMACOLOGY 
Mechanism of action 
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the 
rate-limiting enzyme that converts 3-hydroxy-3 methylglutray1-coenzyme A to 
mevalonate, a precursor of sterols, including cholesterol.  Cholesterol and 
triglycerides circulate in the bloodstream as part of lipoprotein complexes.  With 
ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), 
IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL 
(very-low-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-
density lipoprotein) fractions.  Triglycerides (TG) and cholesterol in the liver are 
incorporated into VLDL and released into the plasma for delivery to peripheral 
tissues.  LDL is formed from VLDL and is catabolized primarily through the high-
affinity LDL receptor.  Clinical and pathologic studies show that elevated plasma 
levels of total cholesterol (total-C), LDL- cholesterol (LDL-C), and apolipoprotein B 
(ApoB) promote human atherosclerosis and are risk factors for developing 
cardiovascular disease. 
Pharmacokinetics and drug metabolism 
Absorption 
Atorvastatin is rapidly absorbed after oral administration; maximum plasma 
concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion 
to Atorvastatin dose.  The absolute bioavailability of atorvastatin (parent drug) is 
approximately 14% and the systemic availability of HMG-CoA reductase inhibitory 
activity is approximately 30%.  The low systemic availability is attributed to 
presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. 
Distribution 
Mean volume of distribution of Atorvastatin is approximately 381 litres. 
Atorvastatin IS >-98% bound to plasma proteins.  A blood/plasma ration of 
approximately 0.25 indicates poor drug penetration into red blood cells. 
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Metabolism 
Atorvastatin is extensively metabolized to ortho- and parahydroxylated 
derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA 
reductase by ortho- and parahydroxylated metabolites is equivalent to that of 
Atorvastatin. Approximately 70% of circulating inhi9bitroy activity for HMG-CoA 
reductase is attributed to active metabolites. 
Excretion 
Atorvastatin and its metabolites are eliminated primarily in bile following 
hepatic and/or extra-hepatic metabolism; however, the drug does not appear to 
undergo enterohepatic recirculation. Mean plasma elimination half-life of 
Atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory 
active metabolites. Less than 2% of a dose of Atorvastatin is recovered in urine 
following oral administration. 
Indication & dosage 
Adjunct to diet to reduce elevated LDL, total cholesterol, apo B and 
triglycerides levels in patients with primary hypercholesterolemia and mixed 
dyslipidemia. 
Adults 
Hyperlipidemia: Initial: 10-20 mg once daily; patients requiring >45% 
reduction in LDL-C may be started at 40 mg once daily; range: 10-80 mg once daily  
Primary prevention of CVD: 10 mg once daily 
Dosage Forms: 
  Tablet: 10 mg, 20 mg, 40 mg, 80 mg 
Contraindications & precaution 
Contraindicated in patients hypersensitive to drug with active hepatic disease 
or conditions associated with unexplained persistent elevations of serum 
traniminaselevels,in pregnant or feeding women and in women of child bearing. Use 
cautiously in patients with history of hepatic disorder heavy alcohol use. 
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Special Populations 
 Geriatric 
Plasma concentrations of Atorvastatin (Atorvastatin) are higher 
(approximately 40 % for Cmax and 30% for AUC) in healthy elderly subjects (age 65 
years) than in young adults.  LDL-C reduction is comparable to that seen in younger 
patient populations given equal doses of Atorvastatin (Atorvastatin). 
Paediatric:  Pharmacokinetic data in the paediatric population are not available. 
Gender : 
Plasma concentrations of Atorvastatin (Atorvastatin) in women differ from 
those in men (approximately 20% higher for Cmax and 10% lower for AUC); 
however, there is no clinically significant difference in LDL-C reduction with 
Atorvastatin (Atorvastatin) between men and Women. 
Renal Insufficiency: 
Renal disease has no influence on the plasma concentrations or LDL-C 
reduction of Atorvastatin (Atorvastatin); thus, dose adjustment in patients with renal 
dysfunction is not necessary. 
Hemodialysis: 
While studies have not been conducted in patients with end-stage renal 
disease, hemodialysis is not expected to significantly enhance clearance of 
Atorvastatin (Atorvastatin) since the drug is extensively bound to plasma proteins. 
Hepatic Insufficiency: 
In patients with chronic alcoholic liver disease, plasma concentrations of 
Atorvastatin are markedly increased. 
Drug Interactions: Substrate of CYP3A4 (major); Inhibits CYP3A4 
(weak)Antacids: Plasma concentrations may be decreased when given with 
magnesium-aluminium hydroxide containing antacids (reported with atorvastatin and 
pravastatin). Clinical efficacy is not altered, no dosage adjustment is necessary. 
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Cholestyramine and colestipol (bile acid sequestrants): Reduce absorption of 
several HMG-CoA reductase inhibitors; separate administration times by at least 4 
hours. Cholesterol-lowering effects are additive. 
Clofibrate and fenofibrate may increase the risk of myopathy and 
rhabdomyolysis. CYP3A4 Inhibitors: May increase the levels/effects of atorvastatin. 
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, 
diclofenac, doxycycline, erythromycin, imatinib, isoniazid, /nefazodone, nicardipine, 
propofol, protease inhibitors, quinidine, and verapamil. 
Digoxin: Plasma concentrations of digoxin may be increased by ̴20%. 
Grapefruit juice: May inhibit metabolism of atorvastatin via CYP3A4; more likely 
to occur with lovastatin or simvastatin; avoid high dietary intake of grapefruit juice. 
Niacin may increase the risk of myopathy and rhabdomyolysis. 
Adverse Reactions 
Central nervous system: Insomnia, dizziness, headache 
Cardiovascular: Chest pain, peripheral edemas 
Dermatologic: Rash (1% to 4%) 
Gastrointestinal: Abdominal pain (up to 4%), constipation (up to 3%), diarrhoea (up 
to 4%), dyspepsia (1% to 3%), flatulence (1% to 3%), nausea 
Genitourinary: Urinary tract infection 
Hepatic: Transaminases increased (2% to 3% with 80 mg/day dosing) 
Neuromuscular & skeletal: Arthralgia (up to 5%), arthritis, back pain (up to 4%), 
myalgia (up to 6%). Weakness (up to 4%) 
Respiratory: Sinusitis (up to 6%), pharyngitis (up to 3%), bronchitis, rhinitis 
Miscellaneous: Infection (3% to 10%), flu-like syndrome (up to 3%), allergic 
reaction (up to 3%) 
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3. DRUG PROFILE-II 
PITAVASTATIN CALCIUM 
 
DESCRIPTION 
Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol 
lowering medication class of statins. Like other statins, it is an inhibitor of HMG-CoA 
reductase, the enzyme that catalyses the first step of cholesterol synthesis. 
CHEMICAL NAME 
(3R, 5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3, 5-
dihydroxyhept-6-enoic acid 
Molecular Weight:  421.461 
STRUCTURAL FORMULA: 
 
 
 
Empirical formula:  C25H24FNO4  
CLINICAL PHARMACOLOGY 
Mechanism of Action 
Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-
determining enzyme involved with biosynthesis ofcholesterol, in a manner of 
competition with the substrate so that it inhibits cholesterol synthesis in the liver. As a 
result, theexpression of LDL-receptors followed by the uptake of LDL from blood to 
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liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition 
of cholesterol synthesis in the liver decreases levels of very low density lipoproteins. 
 
Pharmacodynamics 
In a randomized, double-blind, placebo-controlled, 4-way parallel, active-
comparator study with moxifloxacin in 174 healthyparticipants, Pitavastatin was not 
associated with clinically meaningful prolongation of the QTc interval or heart rate at 
daily doses up to16 mg (4 times the recommended maximum daily dose). 
 
Pharmacokinetics 
Absorption: Pitavastatin peak plasma concentrations are achieved about 1 
hour after oral administration. Both Cmax and AUC0-inf increased in an 
approximately dose-proportional manner for single Pitavastatin doses from 1 to 24 mg 
once daily. The absolutebioavailability of Pitavastatin oral solution is 51%. 
Administration of Pitavastatin with a high fat meal (50% fat content) decreases 
pitavastatin Cmax by 43% but does not significantly reduce Pitavastatin AUC. The 
Cmax and AUC of pitavastatin did not differfollowing evening or morning drug 
administration. In healthy volunteers receiving 4 mg pitavastatin, the per cent change 
from baselinefor LDL-C following evening dosing was slightly greater than that 
following morning dosing. Pitavastatin was absorbed in the smallintestine but very 
little in the colon. 
Distribution: Pitavastatin is more than 99% protein bound in human plasma, 
mainly to albumin and alpha 1-acid glycoprotein, andthe mean volume of distribution 
is approximately 148 L. Association of pitavastatin and/or its metabolites with the 
blood cells isminimal. 
 
Metabolism: Pitavastatin is marginally metabolized by CYP2C9 and to a 
lesser extent by CYP2C8. The major metabolite inhuman plasma is the lactone which 
is formed via an ester-type pitavastatin glucuronide conjugate by uredines 5'-
diphosphate (UDP) glucuronosyltransferase (UGT1A3 and UGT2B7). 
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Excretion: A mean of 15% of radioactivity of orally administered, single 32 
mg 14C-labeled pitavastatin dose was excreted in urine,whereas a mean of 79% of the 
dose was excreted in faces within 7 days. The mean plasma elimination half-life is 
approximately 12hours. 
 
Race: In pharmacokinetic studies pitavastatin Cmax and AUC were 21 and 
5% lower, respectively in Black or African Americanhealthy volunteers compared 
with those of Caucasian healthy volunteers. In pharmacokinetic comparison between 
Caucasianvolunteers and Japanese volunteers, there were no significant differences in 
Cmax and AUC. 
 
Gender: In a pharmacokinetic study which compared healthy male and female 
volunteers, pitavastatin Cmax and AUC were 60 and54% higher, respectively in 
females. This had no effect on the efficacy or safety of Pitavastatin in women in 
clinical studies. 
 
Geriatric: In a pharmacokinetic study which compared healthy young and 
elderly (65 years) volunteers, pitavastatin Cmax and AUCwere 10 and 30% higher, 
respectively, in the elderly. This had no effect on the efficacy or safety of Pitavastatin 
in elderly subjects inclinical studies. 
 
Renal Impairment: In patients with moderate renal impairment (glomerular 
filtration rate of 30 – 59 mL/min/1.73 m2) and end stagerenal disease receiving 
hemodialysis, pitavastatin AUC0-inf is 102 and 86% higher than those of healthy 
volunteers, respectively, whilepitavastatin Cmax is 60 and 40% higher than those of 
healthy volunteers, respectively. Patients received hemodialysis immediatelybefore 
pitavastatin dosing and did not undergo hemodialysis during the pharmacokinetic 
study. Hemodialysis patients have 33 and36% increases in the mean unbound fraction 
of Pitavastatin as compared to healthy volunteers and patients with moderate 
renalimpairment, respectively. 
 
In another pharmacokinetic study, patients with severe renal impairment 
(glomerular filtration rate 15 – 29 mL/min/1.73 m2) notreceiving hemodialysis were 
administered a single dose of Pitavastatin 4 mg. The AUC0-inf and the Cmax were 36 
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and 18% higher, respectively, compared with those of healthy volunteers. For both 
patients with severe renal impairment and healthy volunteers, themean percentage of 
protein-unbound Pitavastatin was approximately 0.6%. The effect of mild renal 
impairment on Pitavastatin exposure has not been studied. 
 
Hepatic Impairment: The disposition of Pitavastatin was compared in 
healthy volunteers and patients with various degrees of hepaticimpairment. The ratio 
of Pitavastatin Cmax between patients with moderate hepatic impairment (Child-Pugh 
B disease) and healthyvolunteers was 2.7. The ratio of Pitavastatin AUCinf between 
patients with moderate hepatic impairment and healthy volunteer’s was 3.8. The ratio 
of Pitavastatin Cmax between patients with mild hepatic impairment (Child-Pugh A 
disease) and healthy volunteer’s was 1.3. The ratio of Pitavastatin AUCinf between 
patients with mild hepatic impairment and healthy volunteers was 1.6. Mean 
Pitavastatint½ for moderate hepatic impairment, mild hepatic impairment, and healthy 
were 15, 10, and 8 hours, respectively. 
 
Drug-Drug Interactions: The principal route of Pitavastatin metabolism is 
glucuronidation via liver UGTs with subsequent formationof Pitavastatin lactone. 
There is only minimal metabolism by the cytochrome P450 system. 
 
Warfarin: The steady-state pharmacodynamics (international normalized ratio 
[INR] and prothrombin time [PT]) andpharmacokinetics of warfarin in healthy 
volunteers were unaffected by the co-administration of Pitavastatin 4 mg daily. 
However,patients receiving warfarin should have their PT time or INR monitored 
when pitavastatin is added to their therapy. 
 
Indications and usage 
Pitavastatin is a HMG-CoA reductase inhibitor indicated for: 
• Patients with primary hyperlipidaemia or mixed dyslipidemia as an adjunctive 
therapy to diet to reduce elevated total cholesterol (TC), lowdensity lipoprotein 
cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase 
high-density lipoprotein cholesterol (HDL-C)  
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Contraindications 
 Known hypersensitivity to product components 
 Active liver disease, which may include unexplained persistent elevations in 
hepatic transaminase levels  
 Women who are pregnant or may become pregnant. 
 Nursing mothers. 
 Co-administration with cyclosporine.  
Dosage and Administration 
 Pitavastatin can be taken with or without food, at any time of day Dose 
Range: 1 mg to 4 mg once daily. 
 
Primary hyperlipidaemia and mixed dyslipidemia: Starting dose 2 mg. When 
lowering of LDL-C is insufficient, the dosage may be increased to a maximum of 4 
mg per day.  
 
 Moderate and severe renal impairment (glomerular filtration rate 30 – 59 and 15 - 
29 mL/min/1.73 m2, respectively) as well as end-stage renal disease on hemodialysis: 
Starting dose of 1 mg once daily and maximum dose of 2 mg once daily. 
 
Special Populations 
Paediatric use: Safety and effectiveness have not been established. Renal 
impairment: Limitation of a starting dose of Pitavastatin 1 mg once daily and a 
maximum dose of Pitavastatin 2 mg once daily for patients with moderate and severe 
renal impairment as well as patients receiving hemodialysis. 
 
Drug Interactions 
Erythromycin: Combination increases pitavastatin exposure. Limit 
pitavastatin to 1 mg once daily  
 
 Rifampin: Combination increases pitavastatin exposure. Limit pitavastatin to 
2 mg once daily  
 
Concomitant lipid-lowering therapies: Use with fibrates or lipidmodifying 
doses (³1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 
Caution should be used when prescribing with pitavastatin. Store at room temperature 
between 15°C and 30°C (59° to 86° F). Protect from light. 
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4. REVIEW OF LITREATURE 
 
In a study Calhoun, ET at⁹²we examined whether atorvastatin affects diabetic 
kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) 
varies by kidney status in patients with diabetes. A modest beneficial effect of 
atorvastatin on egger, particularly in those with albuminuria, was observed. 
Atorvastatin did not influence albuminuria incidence. Atorvastatin was effective at 
decreasing CVD in those with and without a moderately decreased eGFR and 
achieved a high absolute benefit. 
In a study performed Area ET al⁹³. FCHL showed lower serum adiponectin levels 
compared to controls. Also normalipaemic relatives of FCHL patients presented 
decreased levels of adiponectin, suggesting a possible common back ground in the 
determination of this abnormality. Overall, these observations indicate that 
hypoadiponectinemia may be and inherent characteristics of the FCHL phenotype. In 
FCHL Patient’s hypoadiponectinemia may be partially corrected by atorvastatin but 
not be fenofibrate treatment. 
Cemil Kaya, ET al⁹⁴. Patients were randomly divided into groups for treatment: 
group 1, atorvastatin, and 20 mg daily (n ¼ 26), and group 2, simvastatin, 20 mg daily 
(n ¼ 26). Blood samples were obtained before and after treatment. After 12 weeks of 
treatment, serum homocysteine levels in group 1 have decreased from 14.3 ± 2.9 to 
10.6 ± 1.7 mmol/L; in group 2, the levels decreased from 13.6 ± 2.1 to 11.1 ± 1.9 
mmol/L. Both two groups, free testosterone and total testosterone declined 
statistically significantly (38.3% and 36.5 %; and 40.6% and 46.0%, respectively). In 
group 1, vitamin B12 increased from 362.1±107 to 478.7 ± 267 pg. /mL; in group 2, it 
increased from 391.3 ± 107 to 466 ± 211 pg. /mol, but the change did not reach 
statistical significance. There was a considerable decline in the homeostatic model 
assessment index in group 1 (40.0% to 32.1 %). Treatment with statins in women with 
PCOS leads to decreased in serum homocysteine levels.(Fetril Steril -2009; 92:635-
42. 2009 by American Society for Reproductive Medicine.) 
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Morteza Enajat, et al⁹⁵. in the study shows that intensive cholesterol lowering 
therapy with a combination of atorvastatin 40 mg/day and Ezetimibe 10 mg/day in 
elderly AF patients receiving standard vitamin K –dependent OAC therapy targeting 
INR levels of 2.5-3.5 leads to minimal, but statistically significant, OAC therapy dose 
modifications only During the first 3 months. No serous bleeding disorders occurred 
during a follow-up of 12 months. The findings of this pilot study support the inclusive 
of elderly patients with AF receiving long-term OAC treatment in large trails 
investigating the beneficial effect of intensive cholesterol- lowering therapy. 
Nakarin Sansanayudh, ET al⁹⁶. Pitavastatin lowered LDL-C levels from 
baseline by 37% compared with 46% in the atorvastatin group (p < 0.001). The 
reduction of total cholesterol (TC) levels from baseline was significantly different 
between the pitavastatin (28%) and atorvastatin (32%) groups (p = 0.005). There was 
no significant difference in the percentage of changes in triglyceride and high-density 
lipoprotein cholesterol levels between groups. The percentage of patients who 
achieved LDL-C goals according to National Cholesterol Education Program–Adult 
Treatment Panel III guidelines was not significantly different between the pitavastatin 
(74%) and atorvastatin (84%) groups (p = 0.220). In addition, both regimens were 
well tolerated, with no patient developing an elevation of more than 3 times the upper 
normal limit of alanine aminotransferase or 10 times that of creatine kinase. The 
monthly cost per percent LDL-C reduction in the pitavastatin group ($0.77) was about 
50% lower than the cost in the Atorvastatin ($1.56) group. 
Mir Abolfazl Ostad et al⁹⁷. the results of our study demonstrate important effects 
of atorvastatin, independent of LDL-Cholesterol reduction, on the vasodilatory 
capacity in patients with CAD in a randomizes trail. These effects mainly affect the 
endothelium but may also extent to protective structural changes of the vascular wall. 
Thus, our data argue against the concept that combination of low dose statin with 
Ezetimibe may replace high dose statin therapy for secondary prevention in patients 
with atherosclerosis. 
Peter S. Sever ET al⁹⁸. 19.342 hypertensive patients were randomised to either 
an amlodipine or an atenolol – based regimen in the ASCOT Blood Pressure – 
Lowering Arm (BPLA). 10.305 subjects with total cholesterol <6.5 mmol/L were 
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further randomised to atorvastatin 10 mg or placebo in the Lipid- Lowering Arm 
(LLA). CHD benefits associated with BP and lipid lowering were larger than 
predicted by pervious observation and trail data. We estimate that compared with pre-
trail treatment, treating about 55 patients with the amlodipine – based regimen and 
atorvastatin would prevent One CHD event per year. 
Robinson ET al⁹⁹. The present double – blind, randomized, 6 week study 
assessed the lipid-lowering efficacy of Ezetimibe/simvastatin 10/20mg versus 
atorvastatin 10 or 20 mg, and Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 
mg in 1.128 patients with hypercholesterolemia and the metabolic syndrome. 
Ezetimibe/simvastatin was more likely to results in lipid treatment end points than 
atorvastatin and was generally well tolerated at the doses compared in our patients. 
Alexander E. Fraley ET al¹⁰⁰.  This study measured OxPL/apoB, lipoprotein (a) 
[ Lp(a) ], and oxidized low-density lipoprotein ( OxLDL ) biomarkers, consisting of 
immunoglobulin IgG and IgM autoantibodies to malondialdehyde  ( MDA ) –low-
density lipoprotein (LDL ) and IgG and IgM apoB-100 immune complexes  ( IC/apoB 
), at baseline and after 16 weeks of treatment with atorvastatin 80 mg/day or placebo 
in 2,342 patients with acute coronary syndromes (ACS ) enrolled in the MIRACL  ( 
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering ) trail. 
Atorvastatin uniformly increased OxPL/apoB levels in all subgroups studied. Future 
studies are warranted to assess whether the increase in OxPL/apoB levels reflects the 
benefit of effective therapeutic interventions and prediction of new CVD events. 
Yoko K, ET al¹⁰¹. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
inhibitor pitavastatin suppressed basal and cytokine-treated EL expression in 
endothelial cells. Concomitant treatment with mevalonate or geranylgeranyl 
pyrophosphate completely  reversed the inhibitory effect of pitavastatin, suggesting 
that geranylgeranylated proteins are involved in the inhibition of EL expression by 
statins. Inhibition of RhoA activity by overexpression of a dominant-negative mutant 
of RhoA or a Rho kinase inhibitor decreased EL levels. Pitavastatin reduced 
phospholipase activities of endothelial cells, and concomitant treatment with 
mevalonate reversed its inhibitory effect. Pitavastatin reduced RhoA activity and EL 
expression in mouse tissues. Furthermore, plasma EL concentrations in human 
subjects were measured by enzyme-linked immunosorbent assays. Plasma EL levels 
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were negatively associated with plasma HDL levels in 237 patients with 
cardiovascular diseases, and pitavastatin treatment reduced plasma EL levels and 
increased HDL-C levels in 48 patients with hypercholesterolaemia. 
Miyuki Y, ET al¹⁰². Both statins and peroxisome proliferator-activated receptor 
(PPAR)_ ligands have been reported to protect against the progression of 
atherosclerosis. In the present study, we investigated the effects of statins on 
PPAR_activation in macrophages. Statins increased PPAR_ activity, which was 
inhibited by mevalonate, farnesylpyrophosphate, or geranyl pyrophosphate. 
Furthermore, a farnesyl transferase inhibitor and a geranyl transferase inhibitor 
mimicked the effects of statins. Statins inhibited the membrane translocations of Ras, 
RhoA, Rac, and Cdc42, and overexpression of dominant-negative mutants of RhoA 
(DN-RhoA) and Cdc42 (DN-Cdc42), but not of Ras or Rac, increased PPAR_ 
activity. Statins induced extracellular signal-regulated kinase (ERK)1/2 and p38 
mitogen-activated. 
Protein kinase (MAPK) activation. However, DN-RhoA and DN-Cdc42 activated 
p38 MAPK, but not ERK1/2. ERK1/2- or p38 MAPK–specific inhibitors abrogated 
statin-induced PPAR_ activation. Statins induced cyclooxygenase (COX)-2 
expression and increased intracellular 15-deoxy-_12,14-prostaglandin J2 (15d-PGJ2) 
levels through ERK1/2- and p38 MAPK–dependent pathways, and inhibitors or small 
interfering RNA of COX-2 inhibited statin-induced PPAR_activation. Statins also 
activate PPAR_ via COX-2–dependent increases in 15d-PGJ2 levels. We further 
demonstrated that statins inhibited lipopolysaccharide-induced tumor necrosis factor _ 
or monocyte chemoattractant protein-1 mRNA expression, and these effects by statins 
were abrogated by the PPAR_ antagonist T0070907 or by small interfering RNA of 
PPAR_ or PPAR_. Statins also induced ATP-binding cassette protein A1 or CD36 
mRNA expression, and these effects were suppressed by small interfering RNAs of 
PPAR_ or PPAR_. In conclusion, statins induce COX-2– dependent increase in 15d-
PGJ2 level through a RhoA- and Cdc42-dependent p38 MAPK pathway and a RhoA- 
and Cdc42-independent ERK1/2 pathway, thereby activating PPAR_. Statins also 
activate PPAR_ via COX-2–dependent pathway. These effects of statins may explain 
their antiatherogenic actions. 
Review Of  Litreatrue 
 
Page | 46  
Department  of Pharmacy Practice, K.M.College  of  Pharmacy 
Adam g. Goodwill ET al¹⁰³. beginning at seven weeks of age, male OZR was 
treated with gemfi brozil, probucol, atorvastatin, or simvastatin (in chow) for 10 
weeks. Subsequently, plasma and vascular samples were collected for 
biochemical/molecular analyses, while arteriolar reactivity and microvessel network 
structure were assessed by using established methodologies after 3,6, and 10 weeks of 
drugs therapy. While the positive impact of chronic statin treatment on vascular 
outcomes in the metabolic  syndrome are independent of changes to total cholesterol, 
and are more strongly associated with improvements to vascular NO bioavailability 
and attenuated inflammation, these results provide both a spatial and temporal 
framework for targeted investigation into mechanistic determinant of vasculopathy in 
the metabolic syndrome. 
Goldstein ET al¹⁰⁴. Laboratory experiments suggest statin reduce stroke severity 
and improve outcomes. The Stroke prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial was a placebo-controlled, randomized trial 
designed to determine whether treatment with atorvastatin reduces strokes in subjects 
with recent stroke or transient ischemic attack (n≤4731). We analysed SPARCL trial 
data to determine whether treatment favourably shifts the distribution of severities of 
ischemic. The present explanatory analysis suggests that the outcomes of recurrent 
ischemic cerebrovascular events might be improved among statin users as compared 
with nonusers. 
Takafumi H, ET al105.  The JAPAN-ACS (Japan Assessment of Pitavastatin and 
Atorvastatin in Acute Coronary Syndrome) study was a prospective, randomized, 
open-label, parallel group study with blind end point evaluation conducted at 33 
centers in Japan. A total of 307 patients with ACS undergoing IVUS-guided 
percutaneous coronary intervention were randomized, and 252 patients had evaluable 
IVUS examinations at baseline and 8 to 12 months’ follow-up. Patients were 
randomly assigned to receive either 4 mg/day of pitavastatin or 20 mg/day of 
atorvastatin. The primary end point was the percentage change in nonculprit coronary 
PV. The mean percentage change in PV was _16.9 _ 13.9% and _18.1 _ 14.2% (p _ 
0.5) in the pitavastatin and atorvastatin groups, respectively, which was associated 
with negative vessel remodeling. The upper limit of 95% confidence interval of the 
mean difference in percentage change in PV between the 2 groups (1.11%, 95% 
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confidence interval: _2.27 to 4.48) did not exceed the pre-defined noninferiority 
margin of 5%. 
Thomasine; T.Mazzoneet al¹⁰⁶. This post hocanalysis compared the effects of 
treatment with Ezetimibe/simvastatin 10/20 mg vs. atorvastatin 10 and 20 mg/day and 
Ezetimibe/simvastatin 10/40 mg/day vs. atorvastatin 40 mg/day on the cholesterol 
content of lipoprotein subclasses in the modified intent-to-treat (mITT) population 
(n≤1013) and in subgroups of patients with triglyceride (TG) levels <200 mg/dl 
(n≤200 mg/dl (2.6 mmol/l) (n≤413). Results: Ezetimibe/simvastatin significantly 
reduced low-density lipoprotein cholesterol (LDL-C) subclasses LDL₁-c, LDL₂-C 
and LDL₃-C; real LDL-C (LDL-C); intermediate-density lipoprotein cholesterol 
(IDL-C) IDL₁-C,IDL₂-C; very  low-density lipoprotein cholesterol  (VLDL-C), 
VLDL₃-C; and remnant-like lipoprotein cholesterol (RLP-C) from baseline more than 
atorvastatin at all dose comparisons (p<0.01) in the mITT population. Significant 
improvements were also observed in high-density lipoprotein cholesterol (HDL-C)  
subclass HDL₃-C at the Ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg and 
highest dose comparisons (p<0.001) and in VLDL₁₊₂-C at the lowest and highest dose 
comparisons (p<0.0001). changes in LDL₄-C and LDL-C 
Ole Faergeman ET al¹⁰⁷. The trials compared atorvastatin 80 mg/day with 
moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 
10 mg/day in TNT) in patients with clinically evident coronary heart disease or a 
history of myocardial infraction. The outcome measurement in the present research 
was CVE occurring after the first year of the trial. After adjusting for age, gender, and 
study, risk of CVEs increased with increasing TGs (p<0.001 for trend across quintiles 
of TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients 
in the lowest Quintile (hazard ration 1.63, 95% confidence interval 1.46 to 1.81) and 
the relation of TGs to risk was apparent even within the normal range of TGS. Even 
slightly increased TG levels are associated with higher risk of recurrence of CVEs in 
statin-treated patients and should be considered a useful marker of risk. 
Akiko Tsujimoto et al¹⁰⁸. We examined effects of a physiologic concentration of 
pitavastatin (0.01 mmol/L) on oxidant-induced apoptosis in cultured human vascular 
smooth muscle cells (VSMCs). Apoptosis was induced in VSMCs by hydrogen 
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peroxide (H2O2, 300 mmol/L), as evidenced by in situ nick end-labeling and 
scanning electron microscopy. This apoptotic response was accompanied by increased 
activation of mitogen-activated protein kinases (MAPKs—ie, increases in the 
phosphorylated forms of extracellular signal-regulated kinase (p-ERK), c-Jun N-
terminal kinase (p-JNK), and p38 MAPK (p-p38 MAPK). Although pitavastatin alone 
did not induce VSMC death, pretreatment with pitavastatin significantly enhanced 
H2O2- induced apoptosis and prolonged activation of JNK and p38 MAPK (for up to 
24 h) but not ERK. Expression of MAPK phosphatase-1 (MKP-1) also was 
upregulated by H2O2, but this was not affected by pitavastatin. The apoptosis 
accelerating effect was observed also in simvastatin but not in pravastatin. Treating 
VSMCs with mevalonate, farnesyl pyrophosphate, or geranylgeranyl pyrophosphate 
completely blocked the statin-induced enhancement of VSMC apoptosis, suggesting 
that protein prenylation is critically involved. It thus appears that pitavastatin 
enhances H2O2-induced VSMC apoptosis, at least in part, via increases in MAPK 
activation and protein prenylation, but independently of MKP-1 expression, which 
consequently results in reduction of VSMC population.  
Hitoshi Ando, ET al¹⁰⁹. Aims: To compare the effects of grapefruit juice (GFJ) 
on the pharmacokinetics of Pitavastatin and atorvastatin. Methods: In a randomized, 
four-phase crossover study, eight healthy subjects consumed either GFJ or water t.i.d. 
for 4 days in each trial. On each final day, a single dose of 4 mg pitavastatin or 20 mg 
atorvastatin was administered. Results GFJ increased the mean AUC 0 -24 of 
atorvastatin acid by 83% (95% CI 23–144%) and that of pitavastatin acid by 13% (-3 
to 29%).Conclusions: Pitavastatin, unlike atorvastatin, appears to be scarcely affected 
by the CYP3A4-mediated metabolism.  
Kouji Kajinami, et al¹¹⁰. The use of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors, statins, has been shown to reduce major 
cardiovascular events in both primary and secondary prevention, and statins became 
one of the most widely prescribed classes of drugs throughout the world. Previously, 
statins have been well tolerated and have shown favorable safety profiles. However, 
the voluntary withdrawal of cerivastatin from the market because of a 
disproportionate number of reports of rhabdomyolysis-associated deaths drew 
attention to the pharmacokinetic profile of statins, which may possibly have been 
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related to serious drug-drug interactions. Pitavastatin (NK-104, previously called 
itavastatin or nisvastatin, Kowa Company Ltd., Tokyo) is a novel, fully synthetic 
statin, which has a potent cholesterol-lowering action. The short-term and long-term 
lipid-modifying effects of pitavastatin have already been investigated in subjects with 
primary hypercholesterolemia, heterozygous familial hypercholesterolemia, 
hypertriglyceridemia, and type-2 diabetes mellitus accompanied by hyperlipidemia. 
Within the range of daily doses from 1 to 4 mg, the efficacy of Pitavastatin as a lipid-
lowering drug seems to be similar, or potentially superior, to that of atorvastatin. 
According to the results of pharmacokinetic studies, pitavastatin showed favorable 
and promising safety profile; it was only slightly metabolized by the cytochrome P450 
(CYP) system, its lactone form had no inhibitory effects on the CYP3A4-mediated 
metabolism of concomitantly administered drugs; P-glycoprotein-mediated transport 
did not play a major role in its disposition, and pitavastatin did not inhibit P-
glycoprotein activity.  
Tomoya Mita1, E Tal¹¹¹. Aims/Introduction: The distinct effects of different 
statins on glycemic control have not been fully evaluated. In this open-label, 
prospective, cross-over clinical trial, we compared the effects of pitavastatin and 
atorvastatin on glycemic control in type 2 diabetic patients with hypercholesterolemia. 
Materials and Methods: A total of 28 Japanese type 2 diabetics with 
hypercholesterolemia treated with rosuvastatin (2.5 mg/day) for at least 8 weeks were 
recruited to this quasi-randomized cross-over study. At study entry, the patients 
assigned to sequence 1 received pitavastatin (2 mg/day) for 12 weeks in period 1 and 
atorvastatin (10 mg/day) for another 12 weeks in period 2, whereas patients assigned 
to sequence 2 received atorvastatin (10 mg/day) for 12 weeks in period 1 and 
pitavastatin (2 mg/day) for another 12 weeks in period 2. Blood samples were 
collected at three visits (baseline, after 12 and 24 weeks). Results: Lipid control was 
similar in both statins. The difference in glycated hemoglobin between pitavastatin 
and atorvastatin treatments was _0.18 (95% confidence interval _0.34 to _0.02; P = 
0.03). Compared with atorvastatin, pitavastatin treatment significantly lowered the 
levels of glycoalbumin, fasting glucose and homeostasis model assessment of insulin 
resistance. Conclusions: Our results showed that treatment with pitavastatin had a 
more favorable outcome on glycemic control in patients with type 2 diabetes 
compared with atorvastatin.  
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Ping-Yen Liu, ET al¹¹². Evidence about the efficacy and safety of statin treatment in 
high-risk patients with hypercholesterolemia is available for some populations, but 
not for ethnic Chinese. To test the hypothesis that treatment with pitavastatin (2 
mg/day) is not inferior to treatment with atorvastatin (10 mg/day) for reducing 
lowdensity lipoprotein cholesterol (LDL-C), a 12-week multicenter collaborative 
randomized parallel-group comparative study of high-risk ethnic Chinese patients 
with hypercholesterolemia was conducted in Taiwan. In addition, the effects on other 
lipid parameters, inflammatory markers, insulin-resistance-associated biomarkers and 
safety were evaluated. Methods and Results: Between July 2011 and April 2012, 251 
patients were screened, 225 (mean age: 58.7 ± 8.6; women 38.2% [86/225]) were 
randomized and treated with pitavastatin (n = 112) or atorvastatin (n = 113) for 12 
weeks. Baseline characteristics in both groups were similar, but after 12 weeks of 
treatment, LDL-C levels were significantly lower: pitavastatin group = ­35.0  14.1% 
and atorvastatin group = ­38.4 ± 12.8% (both: p < 0.001). For the subgroup with 
diabetes mellitus (DM) (n = 125), LDL-C levels (­37.1 ± 12.9% vs. ­38.0 ± 
13.1%, p = 0.62) were similarly lowered after either pitavastatin (n = 63) or 
atorvastatin (n = 62) treatment. Triglycerides, non-high density lipoprotein 
cholesterol, and apoprotein B were similarly and significantly lower in both treatment 
groups. In non-lipid profiles, HOMA-IR and insulin levels were higher to a similar 
degree in both statin groups. Hemoglobin A1C was significantly (p = 0.001) higher in 
the atorvastatin group but not in the pitavastatin group. Both statins were well 
tolerated, and both groups had a similar low incidence of treatment-emergent adverse 
events. Conclusion: Both pitavastatin (2 mg/day) and atorvastatin (10 mg/day) were 
well tolerated, lowered LDL-C, and improved the lipid profile to a comparable degree 
in high-risk Taiwanese patients with hypercholesterolemia. 
 
R.C. Maranhaol ET al¹¹⁷.We studied 56 CAD patients (56p5 yo) confirmed by 
cineangiocoronariography; 28 patients were being treated with 20 mg/day simvastatin 
and 28 were not treated. An artificial nanoemulsion (LDE) was used as lipid donor to 
HDL LDE labelled with 3H-TG and 14C-FC or 3H-CE and 14C-PL was incubates 
with plasma samples for 1h. After chemical precipitation, the supernatant containing 
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HDL was counted for radioactivity; HDL size was measured by laser-light-scattering. 
Our results show that simvastatin is able to modify the lipid flux to HDL, which may 
change the composition and metabolism of the lipoprotein. The diminished ability to 
received lipids, which is consistent with diminished CETP action elicited by statin 
use, may increase the stability of the lipoprotein particles. 
Valentine Charlton-Menys et al¹¹⁹. Type 2 diabetes patients randomly allocated 
to 10 mg/day atorvastatin (n≤1154) or to placebo (n≤1196)for 1 year were studied to 
compare spontaneous and statin-induced apolipoprotein B (apo B) concentrations (a 
measure of LDL particle concentration) at LDLC and non-HDL cholesterol (non-
HDLC) concentrations proposed as statin targets in type 2 diabetes. Results: Patients 
treated with atorvastatin produced lower serum apo B concentration at any given 
LDLC concentration than patients on placebo. An LDLC concentration of 1.8 mmol 
(70 mg/dL) during atorvastatin treatment was equivalent to a non-HDLC 
concentration of 2.59 mmol/dL (100 mg/dL) or an apo B concentration of 0.8g/L. At 
the more conservative LDLC targets of 2.59mmol/L (100 mg/dL. At the more 
conservation LDLC target of 2.59 mmol/L (100 mg/dL) and 3.37 mmol/L 
(130mg/dL) for non-HDLC, however, the apo B concentration exceeded the 0.9-g/L 
value anticipated in the recent Consequence Statements from the American Diabetes 
Association and the American College of Cardiology. The apo B concentration 
provides a more consistent goal for statin treatment than the LDLC or non-HDLC 
concentration. 
William Insull et al¹²¹. A Randomized (3:2), Open-label, Blinded Endpoint 
(PROBE) study. Methods following ≤4 weeks without lipid-modifying therapies, 193 
patients with dyslipidemia were treated with NER/S(n≤114; 1000/40 mg/day, weeks 1 
to 4; 2000/40 mg/day weeks 5 to 12) or atorvastatin (n≤79; 40 mg/day, weeks 1 to 
12). Compared to atorvastatin, NER/S had a larger beneficial effect on HDL-
C(primary end point: 30.1 ±2.3% and 9.4± 2.6% respectively; P<.001), and similar 
effects on LDL-C and non HDL-C. Two thirds of patients, treated with NER/S 
concurrently attained LDL-C (CV risk-adjusted goals), HDL-C (≤40 mg/dl), and TG 
(<150mg/dl) targets, compared to one-third of patients treated with atorvastatin 
(P<.001). Flushing was the most common treatment-emergent adverse event (TEAE) 
(67.5% NER/S and 10.1 % atorvastatin; P<.001. Seventy-five per cent of flushing 
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episodes were mild to moderate. More patients treated with NER/S and 10.1% 
atorvastatin; P<.001); the most common TEAE was flushing. Compared to 
atorvastatin, NER/S provided superior improvements in HDL-C and LDL-C. 
Treatment with NER/S should be considered for patient with dyslipidemia requiring 
comprehensive lipid control. 
 
Patricia Tung et al¹²².The Previous studies have shown seasonal variation in 
lipids. To understand whether this variation exists in patient with acute coronary 
syndrome \s receiving statins, we examined data from the PROVE IT- TIMI 22 study. 
At baseline, no significant difference in low density lipoprotein (LDL) cholesterol 
was observed when stratified by season. However, a statistically significant difference 
in high-density lipoprotein cholesterol between winter (37 mg/dl) and summer (39 
mg/dl) was observed (p<0.001) at baseline. On treatment, median LDL cholesterol 
was 102 mg/dl in winter versus 96 mg/dl in summer (p<0.001) for the pravastatin 
group and 68 mg/dl in winter versus 62 mg/dl in summer (p<0.001) for the 
atorvastatin group. Median high-density lipoprotein cholesterol was 43 mg/dl in 
summer versus 39 mg/dl in winter in the atorvastatin group (p<0.001). More 
patentsachieved LDL cholesterol <100 mg/dl in summer at 56% versus 47% in winter 
in the pravastatin group (p≤0.11). Achievement of LDL cholesterol <70mg/dl was 
also higher in summer than winter. In conclusion, this was the first evidence of 
seasonal variability in cholesterol in patient with acute coronary syndromes treated 
with statins. This Variability affected achievements of National Cholesterol Education 
Program goals and may affect management decisions based on season of collection. 
 
Peter H.Jones et al¹²³.  As prospectively planned, data were pooled from three 
randomized, double-blind, phase 3 studies of patients with low-density lipoprotein 
cholesterol (LDL-C) ≤130 mg/dL, triglycerides (TG)≤150 mg/dl. And high-density 
lipoprotein cholesterol (HDL-C) <40mg/dl (men) or <50 mg/dl (women). A total of 
2715 patients were randomly assigned to 12-week treatment with fenofibric acid 135 
mg monotherapy; Fenofibric acid + low-dose statin increased HDL-C (18.1% vs. 
7.4%) and reduced LDL-C (-33.1% vs. -5.1%) versus low-dose statin monotherapy 
and reduced LDL-C (-33.1% vs.-5.1%)versus fenofibric acid monotherapy (p<.001 
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for all). Fenofibric acid+ moderate-dose statin increased HDL-C (17.5% vs. 8.7%) 
and reduced TG (-42.0% vs. -23.7%) versus moderate-dose statin monotherapy and 
reduced LDL-C (-34.6% vs. -5.1%) versus fenofibric acid monotherapy (P<0.001 for 
all). Combination therapy was generally well tolerated, and safety profiles were 
similar to monotherapy. No rhabdomyolysis was reported. 
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5. AIM OF THE STUDY 
The purposes of the study were: 
a. To assess the percentage reduction in lipid levels achieved in pitavastatin and 
atorvastatin. Using optimal guideline based prophylactic treatment of 
dyslipidemia. 
b. To find the co-relation between the pitavastatin and atorvastatin administered 
and changes of lipid levels 
c. To define patient groups who are at high risk for dyslipidemia. 
d. To analyse the percentage of adverse effect in pitavastatin and atorvastatin. 
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6. NEED FOR THE STUDY 
 
Nowadays large numbers of patients are taking Pitavastatin and Atorvastatin. 
Studies are going on in various parts of the world for the efficacy and safety of 
Pitavastatin and Atorvastatin in Dyslipidemia patients. So I selected this topic to find 
out the safety, efficacy and quality of life for Dyslipidemia patients in our population 
who were taking Pitavastatin and Atorvastatin. 
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7. METHODOLGY 
 
This study was conducted in MEENAKSHI MISSION HOSPITAL AND 
RESEARCH CENTRE (MMHRC) in Madurai during July 2014-Feb 2015. 
Study design: Randomized, Prospective and comparative study. 
Sample size: 60 Patients 
A total of 60 patients were included in the study in four groups of 15 patients 
in each group. Group-1 patients received Pitavastatin 1 mg tablet once in a day, 
Group-2 received Atorvastatin 20 mg tablet once in a day, Group-3 patients received 
Pitavastatin 2 mg tablet once in a day, and Group-4 received Atorvastatin 40 mg 
tablet once in a day For a period of 20 weeks. Pre index laboratory test values for the 
5 month period before statin initiation were collected. Post index laboratory test 
values were captured after 9 weeks. At each follow visit, patient were assessed for 
lipid profile, adverse effect was asked. The patients were reviewed, and the lipid and 
safety profiles were repeated. 
Patients measure the lipid level (LDL cholesterol, HDL cholesterol, Total 
cholesterol and triglycerides). Patients were asked to report their assessment of side 
effects during the study 
The Pre index of Post index period was used to estimate the percentage change 
in lipid values for each laboratory value and to determine the efficacy, safety and 
quality of life in Dyslipidemia patient. 
 
INCLUSIOIN CRITERIA 
     1.  Patients aged ≥18 years with hypercholesterolemia and a history of CHD, 
     2.   Clinical evidence of atherosclerosis or a CHD-risk equivalent (other clinical 
form of atherosclerotic disease [peripheral arterial disease, abdominal aortic 
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aneurysm or symptomatic carotid artery disease (transient ischemic attacks, 
stroke of carotid origin, or > 50% obstruction of a carotid artery)] 
   3.  Baseline levels of LDL-C> 100mg/dl 
  4.  HDL-C<40 mg/dl 
  5.  Total cholesterol>200mg/dl 
  6.  Triglycerides > 200 mg/dl and 500 mg/dl 
  7.  Diabetes mellitus or ≥2 risk factors that confer a 10-year CHD-risk score>20% 
were eligible for randomization to the study. 
EXCLUSION CRITERIA 
1. A history of hypersensitivity to statins 
2. Pregnancy/lactation 
3. Active liver diseases/hepatic dysfunction 
4. Patient having history of sever myalgia or myositis. 
5. Serious or unstable medical or psychological condition that could compromise 
the patient’s safety or successful trial participation. 
Statistical Tool 
The information collected regarding all the selected causes were recorded in a 
Master Chart. Data analysis was done with the help of computer using Graph Pad In 
Stat DTCG (GPI v3.0) 
  Using this software frequencies, percentages, means, standard, deviations. 
Student unpaired t-test and ‘p’ values were calculated. Student unpaired t-test was 
used to test the significance of difference between quantitative variables and Yate’s 
test for qualitative variables. A’p’ value less than 0.05 is taken to denote significant 
relationship.  
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8. OBSERVATION AND RESULTS 
 
Clinical characteristics 
In this study totally 100 patients were examined. 80 of them had CAD. Due to 
side effects and other reasons 20 patients discontinued from treatment. 
  Only 60 patients of them had regular treatment. 
The baseline clinical characteristics of patients with Pitavastatin and 
Atorvastatin are summarized in the table. Out of the 60 patients in the study Diabetes 
was present in 20 (20%) and Hypertension in 32 (32%) at baseline. 
These patients were significantly older, had a higher systolic BP and a higher 
incidence of Hypertension 
Age Distribution 
Although the age differed between the Pitavastatin and Atorvastatin group, the 
incidence of Dyslipidemia in patients older than 50 years were higher when compared 
with younger patients.  
Statistical analysis using student unpaired t-test shows that the p-value is 
0.3396 and 0.0773 since the p value is greater than 0.05 the incidence of Dyslipidemia 
in elderly patients is not statistically significant. 
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PROFILE OF CASES STUDIED 
Table.1 Age Distribution 
Age Group Pitavastatin  
1 mg 
Atorvastatin
20 mg 
Pitavastatin    
2 mg 
Atorvastatin 
40mg 
No. % No. % No. % No. % 
Up to 50 
yrs 
6 40 8 53.3 7 46.7 5 33.3 
Above50 
yrs 
9 60 7 46.7 8 53.3 10 66.7 
Total 15 100 15 100 15 100 15 100 
Range 32-68 yrs. 34-66 yrs. 41-65 yrs. 34-77 yrs. 
Mean 54.3 yrs. 50.7 yrs. 51.7 yrs. 
 
57.5 yrs. 
 
SD 10.5 yrs. 108 yrs. 6.0 yrs. 10.06 yrs. 
P Value 0.3396 0.0773 
 
Figure.1 
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Table.2 Sex Distribution 
Sex Pitavastatin      
1 mg 
Atorvastatin     
20 mg 
Pitavastatin       
2 mg 
Atorvastatin     
40 mg 
No % No % No % No % 
Male 13 86.7 12 80 10 66.7 12 80 
Female 2 13.3 3 20 5 33.33 3 20 
Total 15 100 15 100 15 100 15 100 
P 
value 
0.5 0.3408 
 
The Sex differed between the Pitavastatin and Atorvastatin groups, the 
incidence of Dyslipidemia in patients Male were higher when compared with Female 
Patients. 
Since the p Value is greater than 0.05 the incidence of Dyslipidemia in Male 
patients is not    statistically significant. 
Figure.2 
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Table.3 Diabetes Mellitus 
Diabetes 
Mellitus 
Pitavastatin  
1 mg 
Atorvastatin  
20 mg 
Pitavastatin  
2 mg 
Atorvastatin  
40 mg 
 No % No % No % No % 
Present 5 33.33 6 40 5 33.3 4 26.7 
Absent 10 66.7 9 60 10 6.7 11 73.3 
P Value 1.0 0.5 
 
The comparison of Dyslipidemia in Diabetic and Non diabetic patients did not 
show any significant difference. The graphical representation is shown in Figure. 
Figure.3 
 
 
Statistical analysis using student unpaired t-test shows that the p value is 1.0 
and 0.5. Since the p value is greater than 0.05, the Dyslipidemia in DM and Non DM 
patients is not statistically significant. 
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Table.4 Hypertension 
Hypertensio
n 
Pitavastatin    
1 mg 
Atorvastatin     
20 mg 
Pitavastatin      
2 mg 
Atorvastatin      
40 mg 
 No % No % No % No % 
Present 8 53.3 7 46.7 7 46.7 10 66.7 
Absent 7 46.7 8 53.3 8 53.3 5 33.3 
P Value 1.0 0.4612 
 
The comparison of Dyslipidemia in Hypertensive and Non Hypertensive patients did 
not show any significant difference. The graphical representation is show in Figure.4 
 
Figure.4 
 
 
Statistical analysis using student unpaired t-test shows that the p value is 1.0 
and 0.4612. Since the p value is greater than 0.05, the Dyslipidemia in Hypertensive 
and Non Hypertensive patients is not statistically significant. 
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Table.5 Family History 
Family 
History 
Pitavastatin 
1 mg 
Atorvastatin   
20 mg 
Pitavastatin      
2 mg 
Atorvastatin 
40 mg 
 No. % No. % No. % No. % 
Present - - 2 13.3 1 6.7 1 6.7 
Absent 15 100 13 86.7 14 93.3 14 93.3 
P value 0.2414 1.0 
 
There is no significant difference in the Dyslipidemia in family history 
   
 
Figure.5 
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Table.6 Smoking (among males) 
Smoking(among 
males) 
Pitavastatin  
1 mg (13) 
Atorvastatin 
20mg (12) 
Pitavastatin   
2 mg (10) 
Atorvastatin 
40mg (12) 
No % No % No % No % 
Current 
smokers 
- - - - 1 10 1 8.3 
Ex.Smokers 1 7.7 3 25 1 10 1 8.3 
Total smokers 1 7.7 3 25 2 20 2 16.6 
Non smokers 12 92.3 9 75 8 80 10 83 
P values 0.2652 0.6316 
                                                        
 
Figure.6 
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COMPARATIVE EFFICACY 
Table.7 Changes in Total Cholesterol 
Total 
cholester
ol values 
at 
Pitavastati
n  1 mg 
Atorvastati
n 
20 mg 
P 
value 
Pitavastati
n 2 mg 
Atorvastati
n 
40 mg 
P 
value 
First 
Visit 
210.3±16 216.9±18.1 0.1495 243.4±47.1 234.9±34.1 0.618
4 
Second 
Visit 
189.1±3.6 206.7±2.6 0.0354 217.7±4.2 206.3±6.5 0.023
1 
Third 
Visit 
165.4±27.1 182.5±7.9 0.0318 172.4±4.7 180.6±4.1 0.043
2 
Changes during 
Second 
visit 
21.1±18.4 10.1±7.5 0.0195 35.7±4.2 28.5±3.3 0.017
7 
Third 
visit 
46.6±22.7 34.4±7.3 0.0472 68.9±6.2 58.1±7.9 0.025
6 
% of changes during 
Second 
Visit 
10.1±4.0 4.3±3.2 0.0021
4 
15.0±2.9 11.4±2.5 0.045
7 
Third 
Visit 
22.1±2.7 15.7±3.9 0.047 25.4±4.2 22.7±3.7 0.027
7 
 
The comparison of total cholesterol in Pitavastatin and Atorvastatin patients 
were found to be statistically significant. The graphical representation is shown in 
Figure.7 
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  Figure.7 
 
 
It shows that Pitavastatin 1 mg is better than Atorvastatin 20 mg in the 
reduction of total cholesterol and also shows that Pitavastatin 2 mg is better than 
Atorvastatin 40 mg in the reduction of total cholesterol. 
Statistical analysis using student unpaired t-test shows that the p value is less 
than 0.05; the total cholesterol in patient between Pitavastatin and Atorvastatin are 
found to be statistically significant. 
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Table.8 Changes in HDL 
HDL 
Values 
at 
Pitavastati
n 1 mg 
Atorvastati
n 
20 mg 
P value Pitavasta
tin  2 mg 
Atorvastati
n 
40 mg 
P value 
First 
Visit 
40.7±4.7 40.7±4.8 0.9523 41.9±4.9 41.5±4.9 0.6466 
Secon
d Visit 
43.5±3.7 42±6.8 0.1172 46.5±2.4 43.5±3.5 0.0489 
Third 
Visit 
46.9±4.2 42.3±.6 0.0056 49.3±4.2 45.4±4.2 0.0305 
Changes during 
Secon
d visit 
2.8±2.5 1.3±2.8 0.0227 5.6±1.6 2±2.4 0.0209 
Third 
visit 
6.5±2.6 1.6±5.1 0.0006 8.6±2.8 4.5±2.2 0.0465 
% of changes during 
Secon
d Visit 
7.5±7.8 2.9±5.9 0.0378 12.7±4.6 5.1±5.9 0.0033 
Third 
Visit 
16.81±8.6 4.9±11.8 0.0015 20.9±8.8 11.0±13.2 0.047 
 
The Comparison of HDL in Pitavastatin and Atorvastatin patients was found 
to be statistically significant. The graphical representation is shown in Figure.8 
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Figure.8 
 
 
It shows that Pitavastatin 1 mg is better than Atorvastatin 20 mg increase of 
HDL and also shows that Pitavastatin 2 mg is better than Atorvastatin 40 mg increase 
of HDL. 
Statistical analysis using student unpaired t-test shows that the p value is less 
than 0.05; the total cholesterol in patient between Pitavastatin and Atorvastatin are 
found to be statistically significant. 
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Table.9 Changes in LDL 
HDL 
Values 
at 
Pitavastatin  
1  mg 
Atorvastatin 
20 mg 
P value Pitavastatin 2 
mg 
Atorvastatin 
40 mg 
P value 
First 
Visit 
117.7±18.1 127±22.2 0.2365 150.7±36.4 141.8±43.8 0.2538 
Secon
d Visit 
101.3±4.3 115.1±5.7 0.0392 128.9±2.3 122.7±1.9 0.0011 
Third 
Visit 
95.3±2.7 110.4±5.9 0.029 100.7±20.4 105.9±1.4 0.0082 
Changes during 
Secon
d visit 
16.3±4.7 12.7±2.3 0.0355 21.8±2.5 19.1±1.9 0.039 
Third 
visit 
25.7±6.4 17.4±3.5 0.0027 50.9±4.7 36.5±6.5 0.0276 
% of changes during 
Secon
d Visit 
14.0±2.4 9.5±4.7 0.0404 14.6±4.2 10.5±3.1 0.0428 
Third 
Visit 
22.6±3.3 16.6±4.1 0.0259 33±5.4 28±2.7 0.0277 
 
The comparison of LDL in Pitavastatin and Atorvastatin patients was found to 
be statistically significant. The graphical representation is shown in Figure.9 
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Figure.9 
 
 
It shows that Pitavastatin 1 mg is better than Atorvastatin 20 mg in the 
reduction of LDL and also shows that Pitavastatin 2 mg is better than Atorvastatin 40 
mg in the reduction of LDL. 
Statistical analysis using student unpaired t-test shows that the p value is less 
than 0.05; the total cholesterol in patient between Pitavastatin and Atorvastatin are 
found to be statistically significant. 
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Table.10 Changes in TGL 
TGL 
 Values at 
Pitavastatin 1 
mg 
Atorvastatin 
20 mg 
P value Pitavastatin 2 
mg 
Atorvastatin 
40 mg 
P value 
First 
Visit 
19.2.7±38.1 191.9±32 0.8519 181.5±29.9 187.3±31.3 0.6935 
Second 
Visit 
183.1±23.9 184.9±26.7 0.8357 165±21.6 176.9±23 0.8846 
Third 
Visit 
172.1±6.2 187.1±7.4 0.0331 151.8±3.5 169.5±4.7 0.0438 
Changes during 
Second 
visit 
9.6±2.6 7.0±2.4 0.0485 16.5±6.3 11.3±7.2 0.0418 
Third 
visit 
20.3±4.0 4.8±5.7 0.0001 28.8±6.2 23.9±2.8 0.0277 
% of changes during 
Second 
Visit 
2.5±13.4 1.5±21.6 0.3952 10.5±2.3 5.5±3.4 0.0319 
Third 
Visit 
13.8±13.9 7.9±43.4 0.0318 20.8±4.0 10.1±6.3 0.0066 
 
The comparison of LDL in Pitavastatin and Atorvastatin patients was found to 
be statistically significant. The graphical representation is shown in Figure.10 
 
 
 
 
 
 
Observations and Results  
Department  of Pharmacy Practice, K.M.College  of  Pharmacy 
    Page | 72
 
Figure.11 
 
 
It shows that Pitavastatin 1 mg is better than Atorvastatin 20 mg in the 
reduction of Triglycerides and also shows that Pitavastatin 2 mg is better than 
Atorvastatin 40 mg in the reduction of Triglycerides. 
Statistical analysis using student unpaired t-test shows that the p value is less 
than 0.05; the total cholesterol in patient between Pitavastatin and Atorvastatin are 
found to be statistically significant. 
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Table.11 Changes in Systolic BP 
Systolic 
BP at 
Pitavastatin 1 
mg 
Atorvastatin 
20mg 
P value Pitavastatin 
2 mg 
Atorvastatin 
40mg 
P value 
First 
Visit 
136.7±18.4 131.3±15.1 0.4341 133.3±17.2 143.3±13.5 0.1001 
Second 
Visit 
133.3±9.8 130.7±11.6 0.5036 131.3±10.6 135.3±8.3 0.3352 
Third 
Visit 
124.5±9.3 128±6.8 0.3664 131.7±5.8 131.5±6.9 1.0 
Changes during 
Second 
visit 
3.3±15.4 0.7±15.8 0.6362 2.0±15.2 8.0±9.4 0.099 
Third 
visit 
14.5±16.3 3.3±17.2 0.0968 3.3±16.7 13.1±11.1 0.1196 
% of changes during 
Second 
Visit 
1.2±12.312.9 0.4± 0.85 0.4±11.1 5.1±6.7 0.1494 
Third 
Visit 
9.3±12.3 1.3± 0.1503 1.1±12.1 8.6±7.1 0.1466 
 
The comparison of systolic BP in Pitavastatin and Atorvastatin patients did not 
show any significant difference. The graphical representation is shown in Figure 11                             
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Figure.11
 
                                  Table.12 Changes in Diastolic BP 
Diastolic 
BP at 
Pitavastatin 
1 mg 
Atorvastatin 
20 mg 
P value Pitavastatin 
2 mg 
Atorvastatin 
40 mg 
P value 
First 
Visit 
76.7±8.2 76±9.1 0.7406 94.7±5.2 77.3±5.9 0.2184 
Second 
Visit 
78±6.8 78.7±7.4 0.9052 76.7±4.9 78.0±4.1 0.4169 
Third 
Visit 
76.4±5.0 78.9±5.2 0.2736 77.5±4.5 78.5±5.5 0.677 
Changes during 
Second 
visit 
1.3±11.3 2.7±16.6 0.6902 2.0±8.6 0.7±8 0.6269 
Third 
visit 
0.9±9.4 2.7±10.3 0.3541 2.5±8.7 1.5±8.0 0.6008 
% of changes during 
Second 
Visit 
2.9±14.7 4.8±14.7 0.5787 3.3±11.6 1.5±10.6 0.6919 
Third 
Visit 
0.1±13.7 4.9±14.4 0.319 4.0±11.7 2.5±11.0 0.6008 
 
The comparison of Diastolic BP in Pitavastatin and Atorvastatin patients did 
not show any significant difference. The graphical representation is shown in 
Figure.12 
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Figure.12 
 
RELATIONSHIP BETWEEN LIPID PROFILE AND AFTER 
VARIABLES 
Table.13 Incidence of Side effects 
Side 
Effects 
Pitavastatin      
1 mg 
Atorvastatin   
20 mg 
Pitavastatin     
2 mg 
Atorvastatin     
40 mg 
 No % No % No % No % 
Yes 1 6.7 2 13.3 1 6.7 2 13.3 
No 14 93.3 13 86.7 14 93.3 13 86.7 
P Value 0.5 0.5 
 
The Side effects differed between the Pitavastatin and Atorvastatin groups; the 
incidence of Side effects in Pitavastatin and Atorvastatin patients is not statistically 
significan 
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 Figure.13 
 
 
                                       Table.14 Age and Lipid Profile 
Lipid Profile 
Age 
group 
Total Cholesterol 
mg/dl 
HDL mg/dl LDL mg/dl TGL mg/dl 
Mean SD Mean SD Mean SD Mean SD 
Less 
than 
50 
213.6 14.9 42.1 5.2 126.6 16.0 170.2 18.3 
More 
than 
50 
219.5 19.4 37.4 3.8 134.9 12.1 196.9 13.3 
P 
value 
0.6679 0.1248 0.5997 0.6055 
 
The relationship between age and lipid profile patients was found to be 
statistically not significant the graphical representation is shown in fig14 
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Figure.14 
 
Statistical analysis using student unpaired t-test shows that the p value is 
greater than 0.05; the drug used in age and lipid profile patients were found to be 
statistically not significant 
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                                       Table.15 Sex and Lipid Profile 
Sex Total 
Cholesterol 
mg/dl 
 HDL 
mg/dl 
 LDL 
mg/dl 
 TGL 
mg/dl 
 
 Mean SD Mean SD Mean SD Mean SD 
Male 215.9 17.5 40.2 4.5 135.7 33.4 195.6 64.7 
Female 201.8 9.3 43.2 5.0 13.02 35.1 162.0 61.2 
P 
Value 
0.0795 0.1042 0.6152 0.1411 
 
The relationship between Sex and lipid profile patients was found to be 
statistically not significant the graphical representation is shown in figure.15 
 
Figure.15 
 
Statistical analysis using student unpaired t-test shows that the p value is 
greater than 0.05; the drug used in sex and lipid profile patients were found to be 
statistically not significant. 
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Table.16 Diabetes Mellitus and Lipid profile 
DM Total Cholesterol 
mg/dl 
HDL  
mg/dl 
LDL  
mg/dl 
TGL  
mg/dl 
 Mean SD Mean SD Mean SD Mean SD 
Present 216 15.3 39.0 5.5 131.3 27.7 194.7 67.6 
Absent 212.2 18.4 41.6 3.9 136.1 36.4 185.2 64.2 
P 
Value 
0.4512 0.0624 0.8691 0.5885 
 
The relationship between diabetes mellitus and lipid profile patients were 
found to be statistically not significant the graphical representation is shown in 
figure.16 
Figure.16 
 
Statistical analysis using student unpaired t-test shows that the p value is 
greater than 0.05; the drug used in diabetes mellitus and lipid profile patients were 
found to be statistically not significant 
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Table.17 Hypertension and Lipid Profile 
Hypertensive Total 
Cholesterol 
mg/dl 
HDL   
mg/dl 
LDL  
mg/dl 
TGL  
mg/dl 
 Mean SD Mean SD Mean SD Mean SD 
Present 218.3 10.7 39.5 5.3 137.3 11.8 192.1 26.6 
Absent 214.9 10.1 41.9 3.9 132 26 184.1 23.9 
P Value 0.5631 0.6667 0.4999 0.662 
 
The relationship between Hypertension and lipid profile patients were found to 
be statistically the graphical representation is shown in figure.17 
Figure.17 
 
Statistical analysis using student unpaired t-test shows that the p value is 
greater than 0.05; the drug used in hypertension and lipid profile patients were found 
to be statistically not significant 
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Table.18 Family History and Lipid Profile 
Family 
History 
Total Cholesterol 
mg/dl 
HDL  
mg/dl 
LDL  
mg/dl 
TGL  
mg/dl 
 Mean SD Mean SD Mean SD Mean SD 
Present 216 19.8 40.5 0.7 168.5 59.8 169.5 71.6 
Absent 213.4 17.4 40.7 4.8 132.1 30.4 189.8 64.9 
P 
Value 
0.803 0.8017 0.1195 0.5633 
 
   The relationship between Hypertension and lipid profile patients were found to 
be statistically not significant the graphical representation is shown in figure.18 
Figure.18 
 
Statistical analysis using student unpaired t-test shows that the p value is 
greater than 0.05; the drug used in family history and lipid profile patients were found 
to be statistically not significant 
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RELATIONSHIP BETWEEN BLOOD PRESSURE AND AFTER VARIABLES 
Table.19 Age and BP 
Age SBP  
mm Hg 
DBP  
mm HG 
 Mean SD Mean SD 
<50 133.1 17.6 75.6 8.1 
>50 138.5 15.2 76.5 6.5 
 
P value 
 
0.2584 
 
0.5298 
 
 
The comparison of Age and BP in Dyslipidemia patients did not show any 
significant difference. The graphical representation is shown in Figure.19 
Figure.19 
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Table.20 Sex and BP 
Age SBP  
mm Hg 
DBP  
mm HG 
 Mean SD Mean SD 
Male 137.4 17.1 76.0 7.4 
Female 131.5 12.8 76.9 6.3 
 
P value 
 
0.2048 
 
 
0.6517 
 
The comparison of Sex and BP in Dyslipidemia patient did not show any 
significant difference. The graphical representation is show in Figure.20 
Figure.20 
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Table.21 Diabetes Mellitus and BP 
DM SBP mm Hg DBP mm HG 
 Mean SD Mean SD 
Present 141.0 15.5 78.5 5.9 
Absent 133.8 16.4 75.0 7.5 
 
P value 
 
0.0836 
 
0.0526 
 
 
The comparison of DM and BP in Dyslipidemia patients did not show any 
significant difference. The graphical representation is show in Figure.21 
Figure.21 
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Table.22 Hypertension and BP 
Hypertensive SBP  
mm Hg 
DBP  
mm HG 
 Mean SD Mean SD 
Present 142.2 14.1 75.6 7.5 
Absent 129.3 16.3 75.7 6.9 
 
P value 
 
0.002 
 
 
0.6913 
 
The comparison of Hypertension and systolic BP in Dyslipidemia patients 
were found to be statistically significant. But the diastolic BP did not show any 
significant difference. The graphical representation is show in Figure.22 
Figure.22 
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Table.23 Family History and BP 
Family 
History 
SBP mm Hg DBP mm HG 
 Mean SD Mean SD 
Present 127.5 20.6 80.0 8.2 
Absent 136.8 16.1 75.9 7.1 
 
P value 
0.3127 0.2921 
 
The comparison of Family History and BP in Dyslipidemia patients did not show any 
significant difference. The graphical representation is show in Figure.23 
Figure.23 
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9. DISCUSSION 
The present study was designed to primarily compare efficacy, safety and 
quality of life of Pitavastatin versus Atorvastatin at the doses prescribed in routine 
clinical practice.  Due to the observational nature of this study, dose-to-dose 
comparisons between Pitavastatin and Atorvastatin relied mainly on the sample size 
available in each of the comparator groups.  The sample size a comparison between 
Pitavastatin 1 mg and Atorvastatin 20 mg with Pitavastatin 2 mg and Atorvastatin 40 
mg. 
This was a randomized controlled study, there were some baseline differences 
between Pitavastatin and Atorvastatin treated patients.  Patients were matched on 
relevant characteristics and co morbidities before their data were abstracted.  After 
accounting for age, sex, pre index lipid levels, the risk, and therapy duration, present 
reductions in lipid level remained significantly greater with Pitavastatin compared 
with Atorvastatin. 
In the present study, patients treated with Pitavastatin were more likely to 
attain lipid the lower level than were patients who received Atorvastatin, which was 
statistically significant after accounting for baseline differences between groups.  The 
Pitavastatin -treated patients continued to achieve significantly greater goal attainment 
rates before and after accounting for baseline differences. 
The results of the present study showed Pitavastatin to produce greater 
reductions in lipid levels, namely LDL cholesterol, Total Cholesterol, HDL and 
Triglycerides goal attainment rates compared with Atorvastatin. 
The present study found greater reduction in lipid level with Pitavastatin 1 -2 
mg compared with Atorvastatin 20 - 40 mg. 
The findings of the present study provide valuable information in aiding 
decisions on therapeutic drug selection for patients with Dyslipidemia in actual 
clinical practice settings.  Furthermore, diet and exercise could also influence the 
results of patients’ lipid levels. 
We Classified patients by the risk and assigned them a lipid goal using clinical 
data obtained from their medical records.  Although medical record data are 
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considered high quality, we could not ascertain if some vital information were 
missing from the medical records.  This may have led to some biases that could not be 
assessed. 
Results of the study showed Pitavastatin 1 -2 mg to be a cost-effective 
alternative to Atorvastatin 20-40 mg, both in terms of cost per percentage lipid level 
reduction and cost per patient achieving.  These results are in line with several 
previous cost-effectiveness analyses, which reported Pitavastatin to be more cost 
effective than Atorvastatin, Pravastatin and Simvastatin.  Further economic analyses 
of Pitavastatin are now needed to determine its potential as more cost-effective 
therapy compared with other statins.This study reveals that Pitavastatin at doses of 1 -
2 mg was superior to Atorvastatin 20-40mg based therapies, as it reduced LDL-
Cholesterol by more than the dose of Atorvastatin.  Similarly, it reduced triglycerides 
and total cholesterol more than Atorvastatin therapy and increased HDL by the lower 
two doses more than was achieved on Atorvastatin therapy.  These results are better at 
lower but not at higher dose than these seen in the comparative study of statins in a 
general population, which showed equivalence of 1 mg Pitavastatin and 20 mg 
Atorvastatin. 
Changes in total cholesterol 
The present study was found that low dose of Pitavastatin 1 mg changes the 
total cholesterol level as 22.1%.  Whereas Pitavastatin 1 mg is better than Atorvastatin 
20 mg in the reduction of total cholesterol.And also found that low dose of 
Pitavastatin 2 mg changes the total cholesterol level as 25.4%.  Whereas Atorvastatin 
40mg changes the total cholesterol level 22.7%.  It shows that Pitavastatin 2 mg is 
better than Atorvastatin 40mg in the reduction of total cholesterol which is mentioned 
in table no: 7 
Changes in HDL Level 
The present study was found that low dose of Pitavastatin (1 mg) changes the 
HDL level as 16.8%.  Whereas Atorvastatin (20mg) changes the HDL Level 4.9%.  It 
Shows the Pitavastatin (1 mg) is better than Atorvastatin (20mg) increase of 
HDL.And also found that low dose of Pitavastatin (2 mg) changes the HDL Level as 
20.9%. Whereas Atorvastatin (40mg) changes the HDL Level 11%.  It shows that 
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Pitavastatin (2 mg) is better than Atorvastatin (40mg) increase of HDL which is 
mentioned in table no: 8 
 Changes in LDL Level 
This study was found that low dose of Pitavastatin (1 mg) changes the LDL 
Level as 22.6%. Whereas Atorvastatin (20mg) changes the LDL Level 16.6%.  It 
shows that Pitavastatin (1 mg) is better than Atorvastatin (20mg) in the reduction of 
LDL.And also found that low dose of Pitavastatin (2 mg) changes the LDL Level as 
33%.  Whereas Atorvastatin (40mg) changes the LDL Level 28%.  It Shows that 
Pitavastatin (2 mg) is better than Atorvastatin (40mg) in the reduction of LDL which 
is mentioned in table no:9 
 Changes in Triglycerides Level 
This study was found that low dose of Pitavastatin (1 mg) changes the 
Triglycerides Level as 13.8%.  Whereas Atorvastatin (20mg) changes the 
Triglycerides Level 7.9%.  It shows that Pitavastatin (1 mg) is better than Atorvastatin 
(20mg) in the reduction of Triglycerides.And also found that low dose of Pitavastatin 
(2 mg) changes the Triglycerides Level as 20.8%.  Whereas Atorvastatin (40mg) 
changes the Triglycerides Level 10.1%.  It shows that Pitavastatin (2 mg) is better 
than Atorvastatin (40mg) in the reduction of Triglycerides which is mentioned in table 
no: 10 
Dyslipidemia in Diabetes Mellitus 
Diabetes mellitus is well recognized risk factor for Dyslipidemia.  In the 
present study the diabetes alone was not an independent risk factor for the 
development of Dyslipidemia.  There was no significant difference between diabetics 
and non-diabetics. 
Dyslipidemia in Hypertension 
The comparison of Dyslipidemia in Hypertensive and Non Hypertensive 
patients did not show any significant difference. 
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Incidence of side effects 
Both Pitavastatin and Atorvastatin were well tolerated in this study, and none 
of the reported side effects were unexpected, given the age and underlying medical 
conditions of the patient population.  Most side effects were of mild or moderate 
severity, and were not considered to be treatment-related.  The most commonly 
reported side effect was myalgia, headache. 
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10 Conclusions 
 
Patients treated with Pitavastatin had significantly greater reductions in LDL 
cholesterol, total cholesterol, triglycerides levels compared with those receiving 
Atorvastatin. Patients receiving Pitavastatin were more likely to attain lipid goals 
compared with patients treated with Atorvastatin 
 The recommended starting doses, Pitavastatin (1-2 mg) is more efficacious 
than Atorvastatin (20-40 mg), in terms of cholesterol, HDL, LDL, and TG better in 
the lipid profile. The greater efficacy of Pitavastatin at starting dose should help to 
reduce the need for higher dosage and enable more Patients to achieve recommended 
treatment goals in clinical practice. Moreover there is, improvements in the whole 
lipid profile, including rise in HDL-C. 
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11. SUGGESTIONS 
 
Suggestions for the management of Dyslipidemia, 
1. Regular exercise 
2. Lifestyle modification 
3. Proper intake of drug to control disease 
4. Initially physician may start with the dose of Pitavastatin 2 mg for the patients of 
Dyslipidemia and then they can reduce the dose of Pitavastatin to 1 mg to 
maintain the cholesterol level. 
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APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT HISTORY PROFORMA
 
NAME OF PATIENT    :    
DATE OF BIRTH           : 
AGE IN YEARS              : 
SEX (F/M)                      :  
MARITAL STATUS        :  MARRIED/UNMARRIED 
OCCUPATION                : 
CONTACT ADDRESS     : 
CONTACT NUMBER    : 
DATE OF ADMISSION: 
TODAY’S DATE              : 
HOSPITAL NUMBER     : 
DIAGNOSIS                    : 
CURRENT 
 MEDICATIONS              : 
OTHER MEDICAL ILLNESS, 
CURRENT OF PAST: 
FAMILY HISTORY       : 
SMOKERS (CURRENT/EX) : 
NUMBER OF YEARS OF SMOKING: 
DURATION OF DYSLIPIDEMIA (YEARS): 
PREVIOUS HISTORY OF CHD (YES/NO): 
STUDY DRUG     
 
 
 
 
 
 
 
 
 
LABORATORY INVESTIGATION 
LIPID PROFILE 1ˢᵗ visit 2ⁿᵈ visit 3ᵈ visit 
TOTAL  
CHOLESTEROL 
LEVEL 
   
HDL 
CHOLESTEROL 
LEVEL 
   
LDL 
CHOLESTEROL 
LEVEL 
   
TRIGLYCERIDES 
LEVEL 
   
BLOOD 
PRESSURE 
   
 
ADVERSE EVENTS 
 
   VISIT 2 (WEEK 9) □ YES □NO                       VISIT 3 (WEEK 20) □ YES □NO 
   IF YES PLEASE SPECIFY: 
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